{
  "id": "gout",
  "title": "Gout",
  "lang": "en",
  "source_lang": "en",
  "summary": "Gout is a chronic arthritis caused by urate crystals deposited in joints, typically producing acute, painful attacks in one joint, often in the lower limb, and risking joint damage if untreated.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "gouty arthritis",
    "podagra"
  ],
  "generated_at": "2026-10-09",
  "model": "pro/claude-haiku-5-5",
  "url": "https://aiwiki.page/en/gout/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/gout/",
      "json": "https://aiwiki.page/zh/gout.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Gout is a chronic form of arthritis caused by an inflammatory response to deposited monosodium urate crystals. It typically appears as an acute, self-limiting inflammatory attack in one joint, most often in the lower limb, and it can progress to recurrent arthritis and joint damage if untreated. At the chemical level, the disease begins when metabolic processing of purines leaves too much uric acid in the blood, so that the sodium salt of urate comes out of solution and forms needle-shaped crystals in and around joints. The crystals then trigger the innate immune system through inflammation and cytokine release. Gout is the most common form of inflammatory arthritis in adults in many countries, and it is often grouped with pseudogout as one of the two principal crystal-induced arthropathies.\n\nThe disease matters for three reasons. First, its acute attacks are among the most painful conditions seen in clinical practice, and repeated attacks can leave permanent joint damage and deposits of urate called tophi. Second, gout is tightly linked to other conditions such as obesity, hypertension, chronic kidney disease and cardiovascular disease, so its management also affects the wider metabolic health of patients. Third, gout is a well-characterised model of how a metabolic abnormality can cause an inflammatory disease, which makes it useful for studying the links between enzymes, kidney function and the immune system.\n\nThis entry covers the chemistry and biology of uric acid, the formation of crystals, the immune mechanism behind flares, the stages and clinical features of the disease, its epidemiology and risk factors, diagnosis, and current treatment. It then turns to the history of the disease, the evolutionary origin of human uric acid levels, and open questions in research and access to care."
    },
    {
      "heading": "Definition and clinical features of gout",
      "text": "Gout is a crystal-induced arthritis. Its root cause is the deposition of monosodium urate monohydrate (MSU) crystals in and around joints, a process that most often produces recurrent acute attacks or, later, chronic arthritis. Gout is caused by monosodium urate monohydrate crystals; pseudogout is caused by calcium pyrophosphate (CPP) crystals and is more accurately termed calcium pyrophosphate disease (CPPD). Pseudogout, now usually called calcium pyrophosphate deposition disease, differs in both the crystal and the distribution of joints. It tends to involve larger joints such as the knee or wrist, whereas gout frequently begins in the big toe. Under polarized light the two crystal types also look different: MSU crystals are needle-shaped and negatively birefringent, while CPPD crystals are rhomboid and positively birefringent. Clinically, however, the two conditions can look very similar, since both cause sudden pain, redness and swelling.\n\nThe acute attack typically comes on rapidly. Within hours, the affected joint becomes painful, warm, swollen and red, and the pain is often severe enough to disturb sleep. The initial attack (flare) of gout is usually monoarticular and often involves the first metatarsophalangeal joint. Involvement of this joint at the base of the big toe is so characteristic that it has its own name, podagra. Other sites include the midtarsal joints, ankles, knees, wrists, elbows and fingers. Other common sites include the midtarsal joints, ankles, knees, fingers, wrists, and elbows. Early in the disease, the attacks are typically confined to a single joint, and the clinical history and examination often point toward gout before crystals are confirmed.\n\nUntreated gout follows a recognisable course. Individual flares are self-limited: they usually subside over days to a few weeks, even without treatment, and the joint returns to near-normal between attacks. With time, however, the intervals between attacks shorten, the flares last longer, and more joints become involved. Attacks become more frequent, last for longer, and involve more joints. After a decade or more of recurrent attacks, some patients develop chronic polyarticular disease with persistent symptoms and destructive joint changes. Chronic tophaceous gout frequently occurs after 10 years or more of recurrent polyarticular gout.\n\nGout also produces extra-articular and systemic manifestations. Its hallmark is the tophus, a collection of urate crystals in soft tissue that appears as a firm lump under the skin, typically around joints, the ear helix or the elbow. Approximately 12-35% of all patients with gout develop tophaceous gout. Large tophi can erupt through the skin and discharge chalky material, and the resulting sinus tracts may become infected. Tophi may erupt through the skin, discharging chalky masses of urate crystals. These sinus tracts can become infected. Ulceration is nonetheless uncommon: despite the high prevalence of tophaceous gout, ulceration is surprisingly uncommon and is an exception rather than the rule. Tophi within and around joints can cause deformity and secondary osteoarthritis. Kidney involvement is another major feature. About 20% of patients with gout have urinary tract stones and can develop an interstitial urate nephropathy. Obstruction of the urinary tract and infection are recognised complications, and untreated progressive renal dysfunction, most often related to coexisting hypertension or, less often, some other cause of nephropathy, further impairs excretion of urate, accelerating crystal deposition in tissues."
    },
    {
      "heading": "Uric acid and purine metabolism",
      "text": "Purines (adenine and guanine) are components of the nucleotides that make up DNA and RNA. Because cells are constantly renewed and dietary nucleic acids are continually digested, the body is always breaking purines down. The degradation pathway starts with nucleotides such as inosine monophosphate, adenosine monophosphate and guanosine monophosphate, which are converted to nucleosides and then to the free bases hypoxanthine and guanine by nucleotide and purine nucleoside phosphorylase reactions. Guanine is deaminated to xanthine, and hypoxanthine is oxidised to xanthine. Xanthine is then oxidised to uric acid. The last two oxidations are catalysed by xanthine oxidoreductase (XOR), which exists in interconvertible dehydrogenase and oxidase forms. The oxidase form generates reactive oxygen species, including superoxide and hydrogen peroxide, as by-products. At physiological pH, uric acid is a weak acid, and most of it circulates in plasma as its monovalent salt, urate. This is why the blood concentration is usually reported as urate.\n\nIn most mammals, a further enzyme, uricase (urate oxidase), converts urate into allantoin, a far more soluble compound that is readily excreted. Humans cannot make active uricase. The loss results from mutations in the uricase gene that introduce premature stop codons, and it is commonly dated to roughly 13 to 24 million years ago, during the evolution of the ancestors of humans and great apes. As a result, purine catabolism in humans terminates at uric acid, which has limited solubility in water. Some gut bacteria are able to degrade uric acid, and this microbial activity is considered a possible partial compensation for the lost enzyme, although its quantitative importance is not established.\n\nUric acid has physiological roles beyond being a waste product. Urate and ascorbate are both strong reducing agents, and a proposed explanation for the loss of uricase is that in higher primates urate partly took over the antioxidant role that ascorbate could no longer fill. Estimates of its share of plasma antioxidant capacity vary between sources, ranging from about half to about two-thirds. Urate can also act as a pro-oxidant under some conditions, and its antioxidant activity is reduced in hydrophobic environments. The total body urate pool is roughly 1 to 1.2 g, with a daily turnover of about 0.6 to 0.7 g. Approximately two-thirds of body urate is produced endogenously and about one-third derives from dietary purines. Serum urate concentration therefore reflects the balance between production and elimination, and a rise can result from overproduction, underexcretion, or both.\n\nMost elimination occurs through the kidneys, which excrete roughly two-thirds of the daily urate load, while the gastrointestinal tract accounts for the remaining third. In the kidney, urate is filtered almost completely at the glomerulus, and the proximal tubule then reabsorbs and secretes it, so the fractional excretion in healthy adults is only about 8 to 10 percent. Urate reabsorption depends mainly on URAT1 (encoded by SLC22A12) on the apical membrane of proximal tubular cells, with GLUT9 (encoded by SLC2A9) on the basolateral side. Secretion involves transporters including OAT1 and OAT3 on the basolateral membrane and NPT1, NPT4 and ABCG2 (also known as BCRP) on the apical side. Loss-of-function variants of SLC22A12 are associated with low serum urate, whereas variants of ABCG2 reduce urate efflux and are among the strongest genetic determinants of gout identified in genome-wide association studies. ABCG2 is also expressed on the intestinal epithelium, where it pumps urate from enterocytes into the lumen. Intestinal excretion accounts for about 30 percent of elimination and becomes proportionally more important when renal function declines, which makes it a compensatory route in chronic kidney disease.\n\nBecause urate handling depends on several transporters acting in sequence, changes in any of them can shift the balance between production and excretion. Disruption at the renal or intestinal level can produce hyperuricemia even when purine production is normal, which is why hyperuricemia is classified by mechanism into overproduction, underexcretion and mixed types."
    },
    {
      "heading": "Hyperuricemia and the solubility threshold",
      "text": "Hyperuricemia means a serum urate concentration high enough that urate can no longer stay fully dissolved in plasma. The most widely used cut-off is about 6.8 mg/dL (roughly 0.4 mmol/L, or about 400 μmol/L). This figure reflects the solubility of sodium urate in biological fluids at physiological pH and 37 °C. Above it, plasma is supersaturated, and monosodium urate crystals can form. Other thresholds appear in the literature. Some guidelines and laboratories use values near 6.0 mg/dL, and many laboratory reference intervals are set from population means rather than solubility, so the operational definition varies with the setting and affects prevalence estimates.\n\nThe threshold is a physicochemical boundary. Uric acid is a weak acid with a pKa of about 5.8, so at blood pH nearly all of it exists as the more soluble urate anion, which pairs with sodium. Solubility falls at lower temperatures, which helps explain why crystals tend to form in cooler peripheral tissues such as the distal joints and the ear, and why the first attack often affects the big toe. Solubility also depends on local conditions in tissue fluid, so a plasma value close to the threshold does not by itself predict where or when crystals will appear.\n\nSerum urate reflects a balance between production and elimination. Production depends on purine turnover, in which the enzyme xanthine oxidoreductase plays a central role. Elimination occurs mainly through the kidney, where urate is filtered and then largely reabsorbed in the proximal tubule. Decreased renal excretion is by far the most common cause of hyperuricemia, although overproduction contributes in some people, for example through rapid cell turnover or rare inherited enzyme defects. Age, sex, kidney function, diet, alcohol, dehydration, fasting and physical stress can all shift the level. Premenopausal women typically have lower values than men.\n\nHyperuricemia is a necessary but insufficient condition for gout. Supersaturation is the underlying requirement, but it is not sufficient on its own to produce crystal precipitation, and crystals alone do not necessarily trigger inflammation. Most people with persistently high urate never develop gout or urate stones. Nevertheless, the risk of gout rises steeply with serum urate concentration, and the highest concentrations are associated with hazard ratios reported to exceed 60 in cohort data. Nucleation, local temperature, tissue conditions and short-term triggers such as trauma or alcohol intake shape whether supersaturation leads to a clinical attack. Hyperuricemia is also associated with cardiovascular disease, chronic kidney disease and metabolic disorders, although the causal role of urate in these conditions remains debated.\n\nAsymptomatic hyperuricemia is elevated serum urate without any clinical gout. Its management is controversial. Several reviews have argued that the risks of asymptomatic hyperuricemia are small and that long-term urate-lowering treatment has not been shown to prevent gout or kidney disease. A systematic review of trials found insufficient evidence that lowering urate in asymptomatic patients prevents gouty arthritis, renal disease or cardiovascular events. Current European and American recommendations generally advise against urate-lowering drugs in this group and favour lifestyle measures. Other investigators point to a pro-inflammatory profile in people with asymptomatic hyperuricemia, to associations with cardiovascular and renal outcomes, and to newer agents that lower urate while also acting on cardiorenal risk. Whether treatment should begin at a given level, and what target it should aim for, remain open questions that large randomised trials have not yet settled."
    },
    {
      "heading": "Formation and deposition of urate crystals",
      "text": "Crystals form only after urate leaves solution. When excretion is insufficient to keep serum urate below the saturation level of 6.8 mg/dL, hyperuricemia may develop, and urate can crystallize and deposit in soft tissues. Joint fluid is a weak solvent for urate, and the lower temperature in peripheral joints further decreases solubility and promotes crystal formation. Nucleation is also helped by solid surfaces. Materials in and around joints, including collagen fibers, chondroitin sulfate, proteoglycans and cartilage fragments act as nuclei for crystals.\n\nCollagen is the best-studied template. Early in vitro work found that Type I collagen (i.e., present in tendons) promoted MSU crystallization in vitro. More recent experiments indicate that injured (i.e., fibrillated) Type II collagen (i.e., present in cartilage) upregulates MSU crystallization and inflammatory cell recruitment. A 2024 study of cartilage from gout patients described a two-step route in which an amorphous precursor first settles on collagen fibrils from damaged cartilage, and crystalline material develops from that precursor. These distinctive biosignatures are consistent with the template-promoted crystallization of biotic MSU crystals after AMSU at low supersaturation, and their slow growth over long periods of time (possibly years) in hyperuricemic gout patients.\n\nOnce nucleated, crystals enlarge and become the needle-shaped forms seen clinically. Reported lengths vary by source: one reference gives 5–25 μm in length, while another gives 5 to 30 µm in length. In a study of hyperuricemic blood, round-shaped bifringent urate microaggregates (UMA; ≤1 μm in size), which can subsequently grow in a bipolar manner to form needle-shaped monosodium urate crystals (nsMSU; up to 100 μm in size). Growth is not self-limiting. As no intrinsic control mechanisms of MSU crystal formation exist, crystals continue to nucleate and grow while hyperuricaemia persists. In tophi, templated nucleation on tissue fibres and, probably later, secondary nucleation on previously formed crystals both contribute to enlargement. Under the microscope, the crystals are identified by optical behaviour. When examined with a polarizing filter and red compensator filter, they are yellow when aligned parallel to the slow axis of the red compensator but turn blue when aligned across the direction of polarization (ie, they exhibit negative birefringence).\n\nDeposition is strongly site-dependent. At the joints MSU crystals form primarily at the cartilage surface; on occasions also tophi form at joint margins. Crystals in tendons and ligaments tend to cluster at insertion sites. Urate crystal deposits formed at different sites within the joint (including synovial fluid, the articular cartilage surface, and within tendons and ligaments, often at insertion sites) have different physical characteristics. In tendons, imaging suggests that crystals line up with the collagen fibres they grow on. Imaging findings suggest MSU crystal formation in tendons follows the direction of collagen fibres and probably occurs on them, although this is inferred from structural observations rather than direct proof. Beyond the joints, tophi can be deposited in different areas of the body with the common locations being the olecranon bursa and first metatarsophalangeal joint. Deposits also occur in the kidney, where deposition of monosodium urate crystals in the kidney can result in inflammation and fibrosis, leading to reduced renal function or chronic damage.\n\nTophi are the most visible product of long-term deposition. Tophus is a hallmark lesion of chronic gout, formed through the combined effects of monosodium urate (MSU) crystal deposition, persistent inflammation, and progressive tissue fibrosis. Histologically, a mature tophus is organized into zones. Microscopically, tophi appear as organized granulomatous lesions composed of a central crystalline core of MSU crystals surrounded by a cellular corona zone and an outer fibrovascular zone. The corona contains macrophages, plasma cells, T and B lymphocytes, and, to a lesser extent, mast cells. Neutrophil extracellular traps are also thought to contribute, because NETs encapsulate and promote the aggregation of MSU crystals. Over time a dense capsule forms, and the densely packed collagen and poor vascular supply significantly hinder the penetration of urate-lowering therapies into the core of the tophus. Tophi usually appear late. The tophus consists of MSU crystals and chronic granulomatous tissue and typically forms in people with gout who have not been treated with urate-lowering therapy for at least 10 years. Their size ranges widely: they may be as small as sesame or as large as eggs. Finally, a methodological point affects what is seen in tissue sections. Formalin fixation of tissues leads to the dissolution of MSU crystals, resulting in their absence from routinely processed pathological samples and hence neglect."
    },
    {
      "heading": "Inflammatory mechanism of the acute flare",
      "text": "Crystal recognition and uptake\n\nA flare starts when urate crystals that have settled in a joint or soft tissue are detected as danger signals by resident innate immune cells. Pattern recognition receptors on the cell surface and in the cytoplasm can detect MSU crystals, which makes innate immunity central to gout. On the cell surface, Toll-like receptors TLR2 and TLR4 contribute to ingestion, and the co-receptor CD14 binds crystals directly. In one mouse study, CD14-deficient macrophages still took up crystals normally, but released roughly 90% less IL-1β and CXCL1. After engulfment, the generation of reactive oxygen species through NADPH oxidase activation follows crystal phagocytosis, and this in turn activates the NLRP3 inflammasome.\n\nNLRP3 inflammasome and IL-1β\n\nThe NLRP3 inflammasome is the intracellular platform that converts the crystal signal into inflammation. Crystals are thought to supply the second of two signals: MSU crystals usually act as signal 2, while another factor such as alcohol or saturated fatty acids serves as signal 1. Signal 1 supports the early synthesis of pro-IL-1β. Cleavage of pro-caspase-1 to caspase-1 and of pro-IL-1β to IL-1β is regarded as a hallmark of inflammasome activation. The mature cytokine, interleukin-1β, is then secreted. NLRP3 inflammasome activation yields IL-1β, the major inflammatory cytokine driving the flare. Neutrophils can also make IL-1β through this pathway, and they can produce proteases that activate IL-1β independently of caspase-1. The dependence on NLRP3 has been shown mainly in vitro and in animal models, but it is widely accepted as the principal route.\n\nRecruitment of neutrophils and the vascular response\n\nIL-1β acts on the local vasculature and on the recruitment of leukocytes. IL-1β engages its receptor on endothelial cells, which prompts the release of IL-8, a potent neutrophil chemokine. The resulting neutrophil recruitment into the inflamed site produces the dense infiltrate seen in acute gouty synovitis. Gout is characterized by neutrophil infiltration into inflamed joints. Once neutrophils encounter crystals, they behave differently: crystal-induced activation inhibits apoptosis, promotes degranulation and superoxide production, triggers cytokine release, and leads to neutrophil extracellular trap formation. The cardinal signs of the attack, namely pain, swelling, redness and warmth, are attributed to this cascade, in which the NLRP3–IL-1β axis directly mediates the cardinal manifestations of acute gout, including rapid-onset pain, swelling, erythema, and warmth.\n\nWhy the flare resolves\n\nUntreated attacks are self-limiting. Acute gouty arthritis usually resolves spontaneously within a few days, leaving minimal residual damage to the joint. The mechanism of this resolution is less settled, but the cell-death and clearance pathway is the leading candidate. As neutrophils reach the end of their life cycle and undergo apoptosis, macrophages and other neutrophils engulf them, which triggers production of anti-inflammatory cytokines and transforming growth factor β1 (TGFβ1), and TGFβ1 suppresses reactive oxygen species and IL-1β production. Recognition of phosphatidylserine exposed on apoptotic cells provides a further anti-inflammatory signal. Phosphatidylserine-positive surfaces engage the MerTK receptor and induce SOCS3 transcription, and elevated TGFβ has been found in synovial fluid during the resolution phase. Macrophage handling of crystals also matters: uptake of MSU crystals by mature macrophages can be noninflammatory and promote resolution of gouty inflammation. Important gaps remain, and little is known about how and where the inflammasome is regulated during this phase."
    },
    {
      "heading": "Stages and natural history",
      "text": "Gout is commonly described as passing through four stages: asymptomatic hyperuricemia, acute gouty arthritis, intercritical period, and chronic tophaceous gout. Some sources call the last stage advanced gout. The speed of progression is not fixed. It varies considerably from person to person and depends on numerous endogenous and exogenous factors, and the serum urate concentration is among the most influential of these.\n\nAsymptomatic hyperuricemia and the first attack\n\nIn the first stage, urate concentrations are raised but no symptoms occur. The condition is usually accidentally discovered when measuring serum urate. Crystal deposition may nonetheless begin in joints and soft tissues before any pain appears. The annual probability of a first attack in someone with hyperuricemia has been estimated at approximately 0.5-2%, so most people with raised urate do not progress to symptomatic disease within a given year.\n\nThe first acute attack marks the point at which the disease becomes clinically apparent. Attacks typically subside after treatment, and when the acute attack settles down within hours to days following the introduction of colchicine or NSAIDs, patients enter into a remission phase.\n\nThe intercritical period\n\nThe intercritical period is free of symptoms, but the disease is not inactive. Low-grade inflammation persists in previously affected joints, and the same cytokines responsible for the acute flare up can be found at lower concentrations inbetween attacks. Crystal deposition also continues during this interval. Without effective treatment, the flare-free intervals tend to shorten over time, flares become longer and more frequent, and persistent pain and stiffness occur (inflammatory activity is the underlying driver).\n\nFactors that influence flare frequency\n\nSerum urate is the strongest documented determinant of how often flares occur. In a UK Biobank study of 3,613 people with gout, followed for a mean of 8.3 years, higher urate levels at baseline were associated with higher rates of recurrent gout. Flare rates per 1,000 person-years rose steadily across urate bands, from 10.6, 40.1, 82.0, 101.3, 125.3, and 132.8 for serum urate levels of below 6, 6.0-6.9, 7.0-7.9, 8.0-8.9, 9.0-9.9, and 10 mg/dL or higher. Nearly all flares occurred in people whose urate was at or above 5 mg/dL, and most at or above 6 mg/dL.\n\nAbrupt changes in urate also provoke flares. The first months of urate-lowering therapy are a high-risk window, and higher baseline serum urate and greater decrease in serum urate lead to higher risk of gout flares. Interruptions and restarts of allopurinol have likewise been linked to a sharp rise in flare odds among hospitalized patients. Joint involvement also shapes the course: chronic untreated hyperuricemia can lead to polyarticular tophaceous gout from recurrent arthritis.\n\nRadiographic damage\n\nRadiographic change lags well behind symptoms. Early on, normal or periarticular soft-tissue swelling only is seen, because bone erosions appear only after years of crystal deposition. Reported delays vary: one review notes a latent period of about 5 to 10 years between the first clinical symptom and the appearance of specific plain radiographic signs, while another states that typical erosions may not be seen until 6–12 years after the initial acute attack.\n\nEstablished disease shows asymmetric, well-corticated (\"punched-out\") juxta-articular erosions with sclerotic margins. The characteristic overhanging edge forms as an enlarging tophus erodes the cortex while new periosteal bone is laid down around it. Such edges are \"Overhanging edges\" on X-ray, indicative of bony erosions, are highly specific for gout. Because cartilage is spared early, the joint space is often preserved until late, which helps separate gout from inflammatory arthropathies that destroy cartilage early. Narrowing of the joint space generally appears only in long-standing or heavily tophaceous disease.\n\nLong-term outcomes\n\nLong-term damage follows the accumulation of urate. The body urate pool keeps growing while hyperuricemia persists, and this burden is ultimately responsible for the progression of clinical symptoms through the various stages of gout. Tophi may become visible and cause deformity: in advanced disease, tophi can be seen clinically, with obvious deformity demonstrated in hands and foot. Tophi can also erode adjacent bone by pressure even when they are not visible externally. Persistent inflammation, bone erosion and deformity can together reduce joint function, and the extent of destruction generally increases with disease duration and with the length of time urate remains elevated without treatment."
    },
    {
      "heading": "Epidemiology and risk factors",
      "text": "Prevalence and trends\n\nGout is the most common form of inflammatory arthritis, and its burden has grown. The 2021 Global Burden of Disease (GBD) study estimated that 55.8 million people globally had gout in 2020, with an age-standardised prevalence of 659.3 per 100,000, an increase of 22.5% since 1990. Crude prevalence varies much more widely between populations. Reviews summarise national estimates as ranging from 1–4% worldwide, with incidence ranging from 0.1–0.3%. Working-age analyses from the same GBD round report the highest rates in high-income regions such as Australasia and North America, and the lowest in parts of sub-Saharan Africa and Latin America, though these results are from a preprint that has not completed peer review. High-income regions (e.g., Australasia and North America) exhibited the highest WAP gout rates. In contrast, some low-income areas (e.g., parts of sub-Saharan Africa and Latin America) had the lowest.\n\nMost of the projected rise in case numbers reflects demographic change rather than a sharp increase in risk. GBD projections estimate that the total number of prevalent cases will reach 95.8 million in 2050, with population growth being the largest contributor to this increase and only a very small contribution from the forecasted change in gout prevalence. The age-standardised rate itself rose only modestly between 1990 and 2021, and increases in incidence have been reported in many countries over recent decades.\n\nSex and age\n\nGout is considerably more common in men than in women. In the GBD 2021 estimates, the prevalence of gout in 2020 was 3.26 times higher in males than in females and increased with age. Reviews describe the male-to-female ratio as 3:1 to 10:1, with the gap varying by population and setting. In a large UK Biobank analysis, gout was present in 4.1% of men and 0.3% of women, and the odds ratio for men compared with women was about 13.\n\nAge is a strong determinant of risk in both sexes. Gout incidence and prevalence increased by each decade of life, with prevalence increasing to 11–13% and incidence increasing to 0.4% in people older than 80 years. Women tend to present later. According to a 2023 analysis of more than 100,000 adults hospitalized with gout in Spain between 2005 and 2015, women were 10 years older than men, and this age difference is consistent with the hormonal explanation. Estrogen promotes renal urate excretion, so premenopausal women generally have lower serum urate than men. After menopause, falling estrogen levels are associated with rising urate and a higher risk of gout.\n\nModifiable factors\n\nThe main modifiable determinants are those that raise serum urate or increase the risk of crystal formation. Obesity is the most important of these at the population level. In GBD estimates, high BMI accounted for 34.3% of YLDs due to gout and kidney dysfunction accounted for 11.8%. Obesity also interacts with genetic risk. In a women-focused analysis, the excess risk of both combined was higher than the sum of each of obesity and genetic predisposition.\n\nOther modifiable factors include diuretics, which reduce renal urate excretion and are a recognised cause of hyperuricaemia, as well as low-dose aspirin, excess alcohol (particularly beer and spirits), high intake of purine-rich foods, and sugar-sweetened beverages containing fructose. These exposures are discussed in detail in the dietary and pharmacological sections. Renal impairment also belongs in this category of risk, since it reduces urate clearance and is itself both a cause and a consequence of gout in many patients.\n\nNon-modifiable factors\n\nGenetic factors are the most important non-modifiable determinants. The heritability of serum monosodium urate (MSU) concentrations is estimated to range between 40 and 70%. Genome-wide association studies have identified many loci that influence serum urate, and most of these act on renal urate handling. Genome-wide association studies (GWAS) have identified several genetic polymorphisms, mainly affecting renal urate excretion, which alter serum uric acid levels and subsequently the risk of developing gout. The strongest single effect comes from the urate exporter gene ABCG2, whose variants have a larger effect on urate and gout risk in men than in women. A gene–sex interaction was also observed for PDZK1, where the effect appears in men but not in women.\n\nHormonal and reproductive factors add a sex-specific layer to genetic risk. Mendelian randomisation analyses suggest that sex hormones influence urate metabolism with significant sex-specific differences, which may help explain why women's risk changes so markedly around menopause. Kidney function is the other major non-modifiable factor. Because the kidney excretes most of the urate that the body eliminates, a reduced filtration rate raises serum urate, and this relationship is discussed further in the comorbidities section."
    },
    {
      "heading": "Comorbidities and systemic associations",
      "text": "Metabolic and cardiovascular comorbidities\n\nGout rarely occurs in isolation. Hypertension, dyslipidaemia, type 2 diabetes, obesity and metabolic syndrome cluster with it more often than chance alone would predict. A 2007–2008 analysis of the US NHANES survey found hypertension in 74% of people with gout, chronic kidney disease in 71%, diabetes in 26%, prior myocardial infarction in 14%, heart failure in 11% and stroke in 10%. The same analysis noted that comorbidity burden rose with the severity of hyperuricaemia. Studies from Korea and Mexico reported a prevalence of metabolic syndrome among men with gout of 44% and 82%, respectively, compared with about 5% in the Korean general population, which has led some authors to argue that gout should be regarded as a metabolic disease rather than a simple joint disorder.\n\nAmong the components of metabolic syndrome, hypertension has generally shown the strongest association with gout. In a large cross-sectional study from China, hypertension conferred the highest risk among the metabolic abnormalities examined, in both obese and non-obese patients. A 2025 study combining observational analysis with genetic approaches, including Mendelian randomisation, reported that metabolic syndrome remained an independent risk factor for gout after propensity matching, with hypertension and hyperlipidaemia showing the strongest associations. Not all data point in the same direction, however. A UK Biobank cohort found lower gout risk among people with diabetes, hypertension or central obesity, and a meta-analysis reported a reduced risk in diabetes; the authors of the cohort suggested that intensified treatment of these conditions may mask their underlying contribution.\n\nCardiovascular disease and the role of urate\n\nGout is linked to cardiovascular disease, including coronary disease, heart failure, stroke and peripheral arterial disease. In a narrative review, all-cause mortality was reported to be 23% higher among people with gout than among those without, and cardiovascular mortality 30% higher. Hyperuricaemia and gout are associated with a greater risk of cardiovascular events, particularly in people who also have chronic kidney disease.\n\nWhether urate itself contributes to cardiovascular risk remains unresolved. Epidemiological studies have consistently associated asymptomatic hyperuricaemia with cardiovascular disease and its risk factors, and animal studies have described vascular toxicity of soluble urate. Confounding, reverse causation and shared aetiological factors could nonetheless account for much of the observed association, so causality is not established. Proposed mechanisms include chronic inflammation driven by systemic urate deposition, but these remain hypotheses.\n\nKidney involvement\n\nThe kidney is the organ most consistently implicated in gout's comorbidity profile. A meta-analysis reported a pooled prevalence of chronic kidney disease beyond stage 3 of 24% among people with gout, with an unadjusted odds ratio of 4.32 compared with people without gout. A meta-analysis of epidemiological studies reported an adjusted odds ratio of 2.41 for stage 3 or higher disease and of 1.77 for nephrolithiasis. In a US Medicare cohort of adults aged 65 and older, gout was associated with a roughly threefold higher hazard of incident chronic kidney disease, which fell to about 2.6-fold after further adjustment for hypertension, hyperlipidaemia, obesity and coronary artery disease.\n\nThe relationship runs in both directions. Reduced renal urate excretion explains much of the hyperuricaemia seen in kidney disease; one review noted that hyperuricaemia occurs in about 60% of people with chronic kidney disease, and around half of those on the way to dialysis develop it. Conversely, some researchers have proposed that high serum urate may accelerate loss of kidney function, although this is not settled. Gout-related kidney damage includes urinary tract stones and urate nephropathy. Estimates of how often these occur vary: one review gave up to 20% of patients, while another reported about 15%. Within the kidney, tophi can form in the renal interstitium, and biopsy-based observations link medullary tophi to progression of chronic kidney disease. Reduced glomerular filtration rate has been associated with earlier tophus formation, and the presence of tophi at diagnosis has been associated with a faster decline in renal function.\n\nCrystal deposits beyond joints\n\nMonosodium urate deposition was long regarded as largely confined to joints and periarticular soft tissue. Advances in imaging, particularly dual-energy computed tomography, have shown that crystals can be detected in other sites, including the vasculature, kidneys, spine, eyes, skin and gastrointestinal tract. In one imaging study, urate deposits were found in the coronary arteries of 55% of people with gout compared with none of the controls, and in the iliac arteries of 54% compared with 11%. Reports of rarer sites, such as the temporomandibular joint and cutaneous panniculitis, also exist. Because these studies are small and largely cross-sectional, the prevalence of extra-articular deposition and its clinical consequences are not yet well defined.\n\nIf extra-articular urate deposition contributes to comorbidity, it would mean that gout's burden extends well beyond joint symptoms. Current reviews describe gout and hyperuricaemia as systemic metabolic disorders, which implies that management should address metabolic and organ-level risks as well as flares. Whether lowering urate changes the course of these associated conditions is an open question addressed in later sections."
    },
    {
      "heading": "Diagnosis and classification",
      "text": "Gout is still confirmed by demonstrating monosodium urate monohydrate (MSU) crystals in material from the affected site. Identification in synovial fluid or in aspirate from a tophus is the reference standard. Polarization microscopy is the definitive way to diagnose gout. Under polarised light microscopy, the crystals appear as needle-shaped, negatively birefringent structures. Aspiration is not always feasible. Aspiration of smaller joints is technically difficult and painful, and it is performed less frequently in primary care offices. Clinicians therefore combine clinical features, serum urate and imaging when no fluid can be obtained.\n\nThe 2015 ACR/EULAR classification criteria were built to standardise research and trial enrolment rather than to serve as a bedside test. Before 2015, there were three classification criteria for gout and two other sets developed for diagnostic purposes. Earlier sets had substantial limitations in sensitivity and/or specificity. The new criteria use a stepwise structure. An entry criterion requires at least one episode of peripheral joint or bursal swelling, pain, or tenderness. If MSU crystals are found in a symptomatic joint, bursa or tophus, the patient is classified as having gout without further scoring. Otherwise, a points-based score is applied across clinical (pattern of joint/bursa involvement, characteristics and time course of symptomatic episodes), laboratory (serum urate, MSU-negative synovial fluid aspirate), and imaging (double-contour sign on ultrasound or urate on dual-energy CT, radiographic gout-related erosion) domains. A total of 8 or more is required for classification. Within the clinical domain, first metatarsophalangeal involvement scores higher than ankle or midfoot involvement, and erythema, inability to bear touch and difficulty walking each add to the total. In the laboratory domain, a low serum urate level subtracts points. If serum urate is below 4 mg/dL, four points are taken away, and a value of 4 to under 6 mg/dL scores zero.\n\nImaging has become central to the diagnosis of gout. In 2015 the OMERACT ultrasound group defined the double contour sign (depositions of crystals on the cartilage surface), tophus (larger crystal depositions), aggregates (small crystal depositions) and erosion (cortical damage) as the elementary gout lesions. The double contour sign is a hyperechoic band over the cartilage surface that persists regardless of beam angle. It is highly specific in aspiration-proven gout, but its sensitivity is relatively low, and reported sensitivity varies widely across studies, from 0.22 to 0.92. Aggregates are the least reliable lesion between observers. The same sign can occur in calcium pyrophosphate deposition, where the anatomical location of the crystal deposition helps distinguish MSU from CPP deposition. Ultrasound also detects erosions more readily than conventional radiography. Erosions are clearly visualised by ultrasonography, with a higher sensitivity than conventional radiography. On radiographs, an erosion is characterised by a cortical break with a sclerotic margin and an overhanging edge. Radiographs typically reveal these changes only after repeated attacks.\n\nDual-energy computed tomography (DECT) can display urate deposits in colour, and it can locate deposits both inside and outside joints. In one diagnostic study, the sensitivity and specificity of DECT for gout were 0.90 and 0.83, respectively. Its accuracy depends on disease stage. All false negatives occurred in patients with acute, recent-onset gout, and all false positives had advanced knee osteoarthritis. In a Chinese cohort, sensitivity was 35.71% at first onset, 61.54% for under 24 months of disease, and 92.86% beyond 24 months. Artefacts from nailbeds, motion or beam hardening can also mimic deposits, so their exclusion is part of image interpretation.\n\nThe differential diagnosis of acute monoarthritis is broad. Septic arthritis must be excluded urgently, because it can coexist with gout and carries a different treatment. Pseudogout caused by calcium pyrophosphate crystals is the main crystal mimic. Rheumatoid arthritis, trauma, haemarthrosis and cellulitis also enter the differential. Crystal identification and cell counts in the aspirate help separate these conditions. A clinical rule can also help. The Acute Gout Diagnosis Rule helps rule gout in or out using mostly clinical criteria, reducing the need for synovial fluid in highly likely patients. Serum urate may be normal during an acute attack, so a normal value does not exclude gout."
    },
    {
      "heading": "Management of acute flares",
      "text": "Acute gout is treated with anti-inflammatory drugs rather than urate-lowering drugs, which take weeks to work. The 2020 American College of Rheumatology (ACR) guideline strongly recommends oral colchicine, NSAIDs, or glucocorticoids as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH, with the choice based on patient factors and preferences. Trials show low-dose colchicine, NSAIDs, and glucocorticoids delivered orally, intramuscularly, or intra-articularly are similarly effective during an attack, so selection rests mainly on safety and individual circumstances. Early treatment is the other consistent principle. The ACR allows colchicine up to 36 h after the onset of the gouty flare, whereas EULAR favours starting within 12 hours, and many clinicians aim to begin within about a day of onset.\n\nColchicine\n\nLow-dose colchicine is the most specific of the three options. The regimen is an initial 1.2 mg, followed one hour later by 0.6 mg, with no further loading dose on the day of the flare. In a comparison with the older high-dose schedule, this low-dose regimen (1.8 mg total) was as effective as the older high-dose regimen (4.8 mg over 6 hours) but with significantly fewer side effects. The ACR therefore recommends low-dose colchicine, which may carry a reduced risk of adverse effects. Intravenous colchicine should not be used because of serious toxicity. Patients already taking daily prophylactic colchicine need a temporary change: after the loading doses, they wait about 12 hours before resuming the usual maintenance dose. Strong CYP3A4 inhibitors, such as diltiazem, fluconazole and grapefruit juice, raise the risk of toxicity and require careful review.\n\nNSAIDs and glucocorticoids\n\nNSAIDs are given at full anti-inflammatory doses early in the attack and then reduced quickly, typically over a few days. Their suitability depends on kidney function, a history of ulcers or gastrointestinal bleeding, cardiovascular risk, diabetes and other medicines. When these factors rule out NSAIDs, glucocorticoids are commonly used. Oral prednisone is usually started at 30 mg to 40 mg per day until symptom improvement, which should occur in 2 to 5 days. Glucocorticoids can also be given intramuscularly, intravenously, or by intra-articular injection, which is useful when only one joint is involved or oral drugs cannot be taken.\n\nInterleukin-1 blockade\n\nIL-1 inhibitors are reserved for flares that do not respond to, or cannot tolerate, standard drugs. The ACR suggests they may be recommended over no therapy for patients in whom anti-inflammatory drugs are ineffective, poorly tolerated, or contraindicated. Their high cost limits access. Three agents are used: anakinra, rilonacept and canakinumab. A meta-analysis found that the drug class reduced pain more than control treatment at 72 hours, with canakinumab was most effective, and flare recurrence was significantly reduced, an effect attributed mainly to canakinumab. Canakinumab is usually given as a single subcutaneous dose of 150 mg. Anakinra has a much shorter half-life, 6 hours, compared with 7 days for rilonacept and 25 days for canakinumab, and its trials found no differences in change in pain versus comparator groups receiving colchicine, naproxen, or prednisone, with more serious adverse events. No study has directly compared canakinumab with NSAIDs or colchicine.\n\nSupportive care and duration\n\nNon-drug measures are secondary but routine. Topical ice is considered a complementary measure during a flare. Rest and elevation of the affected joint, together with simple analgesia, help relieve symptoms, although the evidence for these measures is limited. The length of treatment depends on the severity of the attack and on how quickly treatment began. Many patients who are treated promptly require treatment for no more than 5 to 10 days, while those with severe flares or a delay in starting treatment may need several weeks. Anti-inflammatory drugs are generally continued until the flare has fully resolved, and the ACR notes that starting urate-lowering therapy during a flare does not prolong symptoms as long as anti-inflammatory cover is provided."
    },
    {
      "heading": "Urate-lowering therapy and treat-to-target strategy",
      "text": "Urate-lowering therapy (ULT) aims to bring serum urate under its saturation point, roughly 6.8 mg/dL, so that deposited crystals can gradually dissolve and new ones stop forming. Lower urate levels are associated with faster disappearance of crystal deposits. ULT is distinct from the drugs used for pain and inflammation during attacks, which do not lower urate.\n\nPrincipal agents\n\nXanthine oxidase inhibitors. Allopurinol is the most widely used ULT and has been available for over 50 years. It is considered the preferred first-line ULT by the 2020 ACR guidelines for gout management. The 2020 guideline strongly recommends allopurinol as the preferred first-line agent over all other ULTs for all patients, including those with moderate-to-severe CKD (stage ≥3). Dosing follows a low-and-slow principle. Starting doses are ≤100 mg/day, or ≤50 mg/day in CKD stages 3 and 4, with the dose raised incrementally every 2 to 5 weeks until urate reaches target. The FDA-approved range is 100 to 800 mg/day, but in many primary care practices doses seldom exceed 300 mg/day. In trials at 300 mg/day, only about 40% of patients reached the target urate of <6.0 mg/dL. Low starting doses also lower the risk of allopurinol hypersensitivity syndrome, and HLA-B*5801 testing is advised before starting allopurinol in patients of Southeast Asian descent and African American patients.\n\nFebuxostat is a nonpurine analogue uricostatic agent. The ACR guideline positions it as the second choice after allopurinol, with starting doses of ≤40 mg per day with dose escalation to reach optimal dosing. Its use is limited by cost considerations and emerging CV safety concerns.\n\nUricosurics and enzyme therapy. Probenecid, a uricosuric agent that increases renal urate excretion, is generally placed below xanthine oxidase inhibitors in patients with CKD. The ACR recommends a xanthine oxidase inhibitor over probenecid for those with CKD stage >3. Pegloticase, an intravenous uricase, is reserved for refractory disease. Pegloticase is recommended against as a first-line therapy. The guideline panel considered an optimal trial of oral medication appropriate before pegloticase, given cost differences and potential adverse effects.\n\nTreat-to-target\n\nTreat-to-target (T2T) means adjusting the dose against repeated serum urate measurements, rather than prescribing a fixed dose. The ACR subcommittee strongly recommended treat-to-target titration over a fixed-dose approach for patients receiving ULT. The standard goal is a stable serum urate target of <6 mg/dL, which is strongly recommended over no target. For patients with tophi, EULAR and ACR guidelines advise maintaining urate below 5 mg/dL in tophaceous disease, with the choice depending on patient characteristics and severity.\n\nThe rationale rests on the association between urate levels and disease activity. In one secondary analysis of the CARES trial, gout flare rates were highest when urate was ≥10 mg/dL and lowest when it was ≤3.9 mg/dL. Achieving the target in practice is uneven. In one institutional audit, only 49% of 491 patients managed by primary care providers reached the target within one year. Regular measurement is therefore part of the strategy, and in the CARES analysis urate was checked at months 0, 3 and 6 and then every six months.\n\nControversies\n\nThe first-attack question remains contested. The 2020 ACR guideline conditionally recommends against starting ULT for patients who have a first gout flare without comorbidities. Exceptions are made for a serum urate of 9 mg/dL or higher, urolithiasis, or stage 3 or greater chronic kidney disease, where shared decision-making is appropriate. Asymptomatic hyperuricemia is treated similarly: urate-lowering therapy has not been shown to be beneficial for patients with asymptomatic hyperuricemia. On timing, the ACR recommends starting urate-lowering therapy during an acute flare-up rather than waiting until it resolves, although earlier guidance was conflicting on this point.\n\nMajor guidelines also diverge on targets and philosophy. The BSR guideline recommended an initial target serum urate level of <300 µmol/L (5 mg/dL) for all people receiving ULT, whereas the NICE guideline set the target at <360 µmol/L (6 mg/dL), with a lower target of 5 mg/dL considered for people with tophi, chronic gouty arthritis or frequent flares. The American College of Physicians took a different approach. Its 2017 guideline advocated a treat-to-symptom rather than treat-to-target approach, and it concluded that the evidence was insufficient to justify escalating therapy to a urate target. Prophylaxis duration is another point of divergence: the ACR and EULAR guidelines recommend continuing prophylaxis for 3–6 months rather than less than 3 months, while the ACP's review found that continuing prophylaxis for more than 8 weeks was more effective than shorter durations."
    },
    {
      "heading": "Prophylaxis and long-term management",
      "text": "Flare prophylaxis during urate-lowering therapy\n\nUrate-lowering therapy (ULT) can paradoxically provoke the disease it is meant to control. Initiating or escalating the dose of ULT often precipitates a gout flare, which may lead patients or practitioners to stop treatment, as they believe the drug has made the gout worse. The proposed mechanism is that flares occurring at ULT initiation result from mobilisation of urate crystals, which is thought to act on macrophages through an IL-1β-mediated pathway. In one ULT trial, flares occurred in roughly 30% to 45% of participants between weeks 8 and 16 of treatment, which is why starting ULT at a low dose and raising it gradually is a central principle.\n\nTo blunt this effect, anti-inflammatory cover is started alongside ULT. Low-dose colchicine or a low-dose NSAID is commonly begun one to two weeks before the first ULT dose and continued for at least three to six months, provided serum urate reaches the target. The 2020 American College of Rheumatology (ACR) guideline strongly recommends anti-inflammatory prophylaxis, such as colchicine, NSAIDs, or prednisone/prednisolone, for at least 3 to 6 months when initiating ULT, with ongoing evaluation and continued prophylaxis as needed. Colchicine at 0.6 mg twice daily is the most widely used regimen. Low doses of colchicine (0.6 mg twice daily) or NSAIDs reduce the risk of gout attacks in patients starting urate-lowering therapy. Longer courses of more than eight weeks appear more effective at preventing flares than shorter ones. The evidence base is nonetheless modest; the NICE review found that the colchicine evidence rested on three small RCTs and had limitations.\n\nTreat-to-target and long-term therapy\n\nThe modern strategy is to titrate ULT until serum urate is held below a fixed threshold. The 2020 ACR guideline gives a strong recommendation for a treat-to-target strategy, with a target serum urate of below 6 mg/dL. During titration, serum urate is typically measured every two to five weeks, and the dose is adjusted until the target is reached. The guideline also strongly recommends allopurinol as first-line ULT, including in patients with chronic kidney disease. Because of the risk of hypersensitivity and flares, starting doses are kept low; for example, allopurinol 100 mg daily or less is advised, or 50 mg daily or less in patients with chronic kidney disease.\n\nOnce stable, ULT is usually continued. The guideline conditionally recommends continuing ULT indefinitely rather than stopping it. Management of chronic gout therefore centres on sustained urate control, periodic review of renal function, and adjustment of doses for comorbidities such as chronic kidney disease. For patients with refractory disease treated with the enzyme pegloticase, guidance calls for checking serum urate before each infusion after the first dose, and for withdrawing oral ULT beforehand so that it does not mask a loss of response; treatment is stopped if serum urate rises above 6 mg/dL.\n\nSafety considerations\n\nGastrointestinal effects are the commonest problem with colchicine. Diarrhoea, nausea and vomiting are common, while more serious effects such as myopathy, rhabdomyolysis, neuropathy or bone marrow suppression are rare. In a UK primary-care cohort, adverse events affected 1 in 15 people taking colchicine, and adverse events other than diarrhoea were uncommon. Prophylaxis-related adverse events were more frequent when allopurinol was started with prophylaxis than in other settings.\n\nCardiovascular safety is a further consideration in drug choice. The 2020 ACR guidelines prefer allopurinol as first-line therapy for all patients, partly because of cost considerations and emerging cardiovascular safety concerns with febuxostat. Colchicine has attracted interest for its possible cardiovascular benefit: randomised trials and cohort studies suggest that colchicine is protective against cardiovascular events, although a randomised trial of its cardiovascular benefit specifically in people with gout has yet to be performed. The link between cardiovascular disease and gout management is discussed elsewhere in this entry.\n\nAdherence\n\nLong-term adherence is the main practical obstacle. In a UK analysis of more than 47,000 newly diagnosed patients prescribed allopurinol, 57% had at least one 30-day gap in their allopurinol use during the first year, and 38% had at least one 90-day gap. Over an average follow-up of nearly six years, 77% of patients had at least one 30-day gap in treatment. In a 2014-era Israeli cohort, only a small minority were fully adherent: 1331 gout patients (17% of the study population) were adherent to allopurinol therapy, while 36% and 47% had partial and poor adherence, respectively. A US veterans cohort found that 12,964 (58.8%) were adherers, 4618 were interrupters (20.9%), and 4474 (20.3%) were discontinuers. Adherence has been associated with patient characteristics: poor adherence is particularly common among women, younger patients and those with fewer comorbidities.\n\nPatients' own beliefs strongly shape persistence. In qualitative work, patients stopped therapy when allopurinol was perceived as ineffective or unnecessary, and discontinuation coincided with flares that occurred despite adherence and with suboptimal advice about gout management. Accurate counselling and regular urate measurement are proposed as ways to improve persistence. Despite the guidelines, over the past two decades there has been no increase in ULT utilisation."
    },
    {
      "heading": "Diet, lifestyle and the evidence on dietary factors",
      "text": "Purine-rich foods\n\nPurine-rich foods were among the first dietary factors examined in prospective research. In a cohort of 47,150 men without gout at baseline, men in the highest quintile of meat intake had a relative risk of 1.41 compared with the lowest quintile, and for seafood the figure was 1.51 (1-1, 1-6). Intake of purine-rich vegetables and total protein showed no association with gout (1-2). The researchers suggested that the uricosuric effect of protein-rich diets may offset the purine load (1-6).\n\nOrgan meats such as liver, kidneys and sweetbreads are among the most purine-dense foods (3-1), and large amounts can raise uric acid and increase the risk of attacks (3-2). Among seafood, sardines, anchovies, herring and haddock are often singled out as high in purines (4-14), whereas salmon contains comparatively less (8-13). Processed, dried and canned fish tend to contain more purines than fresh fish (7-7). Dairy showed the opposite pattern: in the same cohort, the highest dairy intake was associated with a relative risk of 0.56 (1-1).\n\nAlcohol\n\nAlcohol is one of the most consistently reported dietary associations. In a UK Biobank analysis of more than 400,000 adults, beer or cider showed the strongest association, with a hazard ratio of 1.60 in men and 1.62 in women per pint consumed daily (14-1). Champagne or white wine and spirits were also linked to higher risk, and red wine was not among the beverages highlighted in the main analysis (14-1). Sex differences appeared at the level of drinking status: compared with never-drinkers, current drinkers had higher gout risk among men but not among women (14-3).\n\nAlcohol acts through more than one route. Hepatic metabolism of alcohol generates urate, and ethanol also interferes with renal excretion of uric acid (9-6). Case-crossover studies have identified alcohol and purine-rich foods as triggers of acute attacks, consistent with their effects on serum urate (9-8, 9-9). Some reviews propose that moderate wine may have anti-inflammatory properties, but this remains a hypothesis (15-2).\n\nSugar-sweetened beverages and fructose\n\nThe Nurses' Health Study followed 78,906 women for 22 years and documented 778 incident gout cases (26-3, 19-3). Compared with consuming less than one serving per month, one daily serving of sugar-sweetened soda carried a relative risk of 1.74, and two or more daily servings carried 2.39 (19-5). Diet soft drinks showed no association (19-7). The absolute differences were modest, at roughly 36 to 68 additional cases per 100,000 person-years for soda, and the authors judged the population contribution likely limited by the low incidence in women (19-6, 19-8). Among men, two or more daily servings of sugary soft drinks were associated with an 85% higher risk (24-1).\n\nA pooled analysis of cohort and case-control studies estimated about 35% higher gout risk for the highest versus lowest sugar-sweetened beverage intake (21-3). A separate meta-analysis reported a pooled odds ratio of 1.66 for gout with high fructose intake, although the link with hyperuricemia was inconsistent (22-2), and fruit juice showed a weaker association whose confidence interval crossed 1 (22-1). Fructose metabolism contributes to urate through the same hepatic and renal pathways as alcohol (9-6).\n\nWeight, other beverages and protective associations\n\nObesity is one of several factors that contribute to gout alongside comorbidities, genetic predisposition and dietary habits (20-3). Mediterranean-style eating patterns have been studied in relation to both gout and weight loss (8-1). Coffee, dairy products and vitamin C have been associated with lower serum urate and reduced gout risk in observational work (9-5), but these findings have not been established as causal.\n\nLimits of dietary control\n\nDietary modification is considered helpful for reducing recurrence, but it does not replace medication for many patients. Diet can reduce the risk of recurrence, yet treatment options remain limited (20-2). Patients often regard diet as the most important cause of their disease (9-7), and some self-reported food avoidances, such as tomatoes, lack support in the medical literature (9-10). Dietary changes therefore tend to produce limited reductions in serum urate, which is why urate-lowering therapy remains the principal approach for patients whose levels stay high."
    },
    {
      "heading": "History and the cultural image of gout",
      "text": "Gout is one of the oldest described joint diseases. Egyptian medical writing is commonly credited with the earliest account, traditionally dated to 2640 BCE, but the texts that supposedly contain it are now missing, and the claimed early date rests on later references. Greek physicians left more secure evidence. Hippocrates of Kos (5th century BCE) is considered to be the first to have accurately described gout. He called it \"the unwalkable disease\" and explained its attacks through the humoral theory, holding that an abnormal accumulation in the joints of one of the four humours, phlegm caused the swelling. Hippocrates also tied the condition to luxury, describing it as an \"arthritis of the rich\", as opposed to rheumatism, an arthritis of the poor. Later Roman writers continued the association. Aulus Cornelius Celsus described the linkage with alcohol, later onset in women and associated kidney problems, and the fact that women can also develop gout was first recognized during the reign of Nero by Seneca.\n\nMedieval and early modern beliefs\n\nThe modern name derives from medieval humoral thinking. The English term \"gout\" first occurs in the work of Randolphus of Bocking, around 1200 AD. It comes from the Latin gutta, a drop, and reflected the belief that an excess of one of the four 'humors' would, under certain circumstances, 'drop' or flow into a joint, causing pain and inflammation. Treatment followed the same logic. The ancient remedies of bleeding and purging to restore humoral balance remained popular.\n\nThe image of gout as a disease of the privileged took firm shape in this period. Because the lifestyle that led to gout could only be afforded by the affluent, gout has been referred to as the 'disease of kings'. It was historically known as \"the disease of kings\" or \"rich man's disease\" for its relationship to a rich diet and obesity. Because of this association, in some eras gout was perceived as socially desirable because of its prevalence among the politically and socially powerful. From the 16th to the 18th century, many believed gout was an aphrodisiac. Horace Walpole reportedly joked that he regarded the disorder as a remedy rather than a disease.\n\nIn the late seventeenth century, Thomas Sydenham, an English physician who was himself affected, gave one of the most vivid clinical accounts. Patients were often \"awakened by a pain which usually seizes the great toe,\" Sydenham wrote. He likened the sensation to a \"dislocated bone.\" Remedies remained empirical. Thomas Dover invented his Dover's Powders to treat the pain caused by gout using ipecacuanha and opium.\n\nNineteenth-century discoveries\n\nThe chemical basis of gout emerged only in the late eighteenth and nineteenth centuries. Uric acid had been isolated from urinary stones, and in 1797 Woolaston showed that gouty concretions were composed of sodium urate. Earlier observers had noticed the crystals without understanding them: Antonie van Leeuwenhoek, the discoverer of the microscope, had observed and described the presence of needle-like crystals in gouty tophi, but he did not identify their nature. James Parkinson's 1805 work realized the limited solubility of uric acid in water; the somewhat greater solubility of its sodium salt; and the likelihood of surplus urate crystallizing in tissues.\n\nThe decisive step came with Alfred Baring Garrod. In 1848 he presented to the Royal Medical and Chirurgical Society experimental evidence that 'soda of urate' could be crystallized spontaneously out of blood serum, and he showed higher levels in gout than in patients with acute rheumatism or Bright's disease. Sources differ on when his semi-quantitative \"thread test\" was described, with one giving 1854 and another 1859. Garrod's later treatise argued that the deposited urate of soda may be looked upon as the cause, not the effect of the gouty inflammation. Debate continued for decades. Garrod's followers believed the oversaturation of body fluids led to the deposition of crystalline uric acid salts into the tissues. The crystal explanation was not confirmed in joint fluid until the twentieth century, when Daniel McCarty and Joseph Lee Hollander demonstrated the presence of sodium monourate crystals in the synovial fluid of gouty patients in 1961.\n\nGout in art, literature and public perception\n\nGout was a recurring subject in portraiture and anecdote. Historical figures from Henry VIII to Benjamin Franklin have been depicted as tending to swollen, bandaged feet after nights of rich food and heavy drinking. Writers also recorded its agony; in the nineteenth century, Sydney Smith said it felt like \"walking on eyeballs\" when his gout flared up. The social meaning persisted into the modern era. A 1900 remark quoted by historians of the disease held that gout seemed to raise a patient's social status, reflecting the older class-coded view. Modern clinicians reject that framing: gout does not discriminate based on socioeconomic status but rather it is directly related to uric acid metabolism."
    },
    {
      "heading": "Evolutionary origin of human uric acid levels",
      "text": "Inactivation of the uricase gene\n\nMost non-primate mammals keep circulating urate low because the liver enzyme uricase converts it into allantoin, which is far more soluble. Humans and the great apes lack this step. Rather than a single event, the gene was switched off through several separate mutations, some of which created premature stop codons. Uricase mRNA is still present in human liver cells, but the transcripts carry two premature stop codons.\n\nDating the silencing is difficult, and estimates differ. One analysis places the event at about 17 million years ago, during the early Miocene. Another dates the great ape and human silencing to about 15 million years ago and a separate lesser-ape silencing to about 9.8 million years ago. Parallel silencing mutations occurred in the great ape/human clade and the lesser ape clade, and reduced hepatic uricase activity is also documented in Old World monkeys. The process was gradual. Inactivation took place over nearly 50 million years, with full inactivation in the early Miocene, a period that coincided with global climatic cooling. Under those conditions, frugivorous apes experienced periods of starvation, especially during cooler winter months.\n\nThe result is a steady rise in circulating urate. Measurements from apes without functional uricase kept in captivity fell roughly between 2.5 and 3.5 mg/dL, a range that is also seen in some traditional human populations.\n\nCompeting adaptive hypotheses\n\nThe oldest explanation is antioxidant. Ames and colleagues first proposed in the 1980s that uricase deficiency gave early hominids an advantage, because urate neutralises reactive oxygen species such as singlet oxygen and hydroxyl radicals. Urate is a large part of plasma antioxidant capacity, with one review estimating 35% to 65% of total antioxidant capacity of plasma. A related proposal links the change to vitamin C: the loss of uricase may have preserved plasma antioxidant power after ancestors lost the ability to synthesise ascorbate. The timing does not fit well, however. The inactivation of the gene for ascorbate synthesis occurred around 61 million years ago, far earlier than the uricase loss, and human ancestors survived for more than 40 million years without the proposed protection.\n\nA second hypothesis concerns salt conservation and blood pressure. In rats, blocking uricase with oxonic acid produces hyperuricaemia, and when these animals are placed on a low-salt diet their blood pressure rises through activation of the renin–angiotensin system. Fruit-based diets in the Miocene were likely low in sodium, so higher urate may have helped maintain blood pressure. A third, more recent proposal by Johnson, Lanaspa and Gaucher treats the loss of uricase as a thrifty gene. Early primates facing intermittent starvation may have gained a survival advantage from losing uricase, because higher uric acid could have potentiated fructose effects to store fat.\n\nTrade-offs and tests of the hypotheses\n\nSeveral lines of evidence suggest that selection favoured the change. The pattern of occurrence of the mutations shows a redundancy that points toward selective advantage, and parallel mutations also increased renal reabsorption of uric acid. Renal handling is indeed efficient, since 90% of uric acid filtered by the kidneys is reabsorbed rather than excreted.\n\nModern populations, however, experience the costs. In today's environment, the loss of uricase is argued to function as a thrifty gene that raises the risk of obesity and cardiorenal disease. Epidemiological data are also mixed. Because metabolic syndrome is so prevalent, hyperuricemia in association with it would be expected to overwhelm any advantage from higher uric acid, which may explain why hypotheses about longevity or intellectual performance have not been supported in data analyses. In a large cohort, crude mortality rates were 4.50, 5.61 and 10.46 deaths per 1000 person-years for subjects with normouricaemia, hyperuricaemia and gout, respectively.\n\nComparative biology of uricase loss\n\nAnimal models show how strongly uricase function matters. Mice lacking functional uricase die shortly after birth, but they can be rescued by feeding them allopurinol, which blocks conversion of xanthine to uric acid. Uricase-deficient rats have a shortened lifespan, with the direct cause being renal failure from gouty nephropathy. Comparative work also indicates that the enzyme's activity declined steadily in ancestral mammalian lineages before the primate pseudogenization events.\n\nCompensatory mechanisms may also exist. One proposal suggests that gut microbiota play a compensatory role for uricase loss, helping to regulate uric acid levels. Despite these findings, the precise biological reason for the increase in urate in humans and some primates remains unresolved."
    },
    {
      "heading": "Research frontiers and open questions",
      "text": "Next-generation urate-lowering drugs\n\nMuch of the current pipeline targets urate reabsorption in the kidney rather than xanthine oxidase. Dotinurad is a highly selective URAT1 inhibitor that shows minimal inhibition of ABCG2 and of the OAT1 and OAT3 transporters. It was approved in Japan in 2020. A Chinese phase III trial found it superior to febuxostat, a pivotal randomized, double-blind study across 30 sites supporting that result. Regulators in the United States and the European Union have not approved it, which may reflect limited Western phase III data and the emphasis placed on long-term cardiovascular outcomes.\n\nPozdeutinurad (AR882) is further along in Western trials. The agent is currently in phase 3 studies for the treatment of gout and tophaceous gout. In the REDUCE 2 trial of 811 adults, most of whom had not been adequately controlled on earlier therapy, significantly more patients achieved serum urate below 6 mg/dL at six months with pozdeutinurad 50 mg and 75 mg than with placebo. Other agents are less advanced. Epaminurad is in a phase 3 trial against febuxostat, while development of verinurad for gout appears to have been stopped. Renal adverse events and rising creatinine were common with verinurad, a reminder that the safety of URAT1 blockade in chronic kidney disease remains a question for each new compound.\n\nSGLT2 inhibitors and urate\n\nSodium-glucose cotransporter-2 (SGLT2) inhibitors, developed for type 2 diabetes, lower urate by a proposed dual mechanism. They inhibit urate reabsorption through URAT1 in the apical membrane of renal proximal tubules and promote urate excretion through ABCG2. A meta-analysis of 43 randomized controlled trials estimated a mean reduction of 33 μmol/L (0.56 mg/dL). Whether this translates into fewer gout events is less clear. A network meta-analysis found that there was a potential reduction in the incidence of gout with SGLT2 inhibitors, but the difference was not statistically significant. Observational data are more favourable. One Massachusetts General Hospital analysis reported that these drugs reduce recurrent gout flares in patients with gout and type 2 diabetes. Open questions include whether urate reduction explains the benefit at all; one review notes that the clinical benefits probably do not arise solely from urate reduction, and prospective trials in people with gout itself remain needed.\n\nTargeting NLRP3 and IL-1β\n\nBecause gout flares are driven by interleukin (IL)-1β, inhibitors of the NLRP3 inflammasome are being tested as oral alternatives to injected IL-1 blockade. Dapansutrile, a selective oral NLRP3 inhibitor, was evaluated in an open-label phase 2a study that enrolled 34 patients with monoarticular flares; in the 29 included in the per-protocol analysis, target joint pain fell by a mean of 68.4% by day 3 at the 300 mg/day dose. The small, uncontrolled design limits interpretation, and a phase 2/3 trial (PODAGRA) is recruiting to explore the efficacy and safety of OLT1177 in acute gout flares. Injectable IL-1 agents have more data. Anakinra, a short-acting IL-1 receptor antagonist, gave efficacy similar to the traditional oral therapies in two randomized trials, and canakinumab significantly prevented recurrent gout flares over 24 weeks in a randomized trial. Crystal exposure alone does not fully explain flare risk, since it is not sufficient to explain the absence of gout flares in individuals with MSU crystal deposition. Other activators, including extracellular ATP, cholesterol and glucose, are thought to contribute to inflammasome activation, and the factors that decide which crystal-bearing joints flare remain unresolved.\n\nCrystal nucleation and biomineralization\n\nThe mechanisms by which monosodium urate crystals nucleate and grow in specific tissues remain incompletely understood. Collagen fibrils and cartilage are thought to act as templates, but the molecular rules that make some tissues more permissive than others are not established. Framing urate deposition as a biomineralization process, comparable to physiological mineral formation, may help explain why crystals accumulate in some joints and tendons while remaining silent in others.\n\nUrate, cardiovascular disease and kidney outcomes\n\nThe central unresolved question is whether urate is causal in cardiovascular and renal disease, or merely a marker of metabolic risk. Mendelian randomization studies have produced mixed results, and randomized evidence that lowering urate reduces cardiovascular events or slows kidney decline is limited and inconsistent. Safety concerns also arose during earlier trials: febuxostat was associated with higher cardiovascular mortality than allopurinol in one major trial. Some authors argue that a sustained and substantial reduction of serum urate into the normal range appears to be required to reduce CV and renal risk, which would require combination therapy. Whether such reductions alter these outcomes, and whether the answer differs by drug class, is an open question for future trials."
    },
    {
      "heading": "Access to care and health-system gaps",
      "text": "Under-treatment and gaps in guideline-based care\n\nEffective urate-lowering drugs have been available for decades, yet many people with gout do not receive care that follows current guidelines. The main gap is the treat-to-target approach, in which the dose is adjusted until serum urate falls below the goal. In a retrospective cohort of 5,985 patients who started allopurinol at a single US institution between 2015 and 2020, only 48.3% had their urate level measured within six months. Dosing is a second weak point. Allopurinol 100 mg and 300 mg tablets are the strengths most often prescribed, and doses of 300 mg or less often fail to reach the target in people with normal kidney function. In one observational study, 67% of patients taking 100 mg daily needed their dose increased, compared with 16% of those taking 300 mg. Reviews attribute these shortfalls to both physician and patient factors, and specifically point to low adherence by primary-care physicians to evidence-based guidelines.\n\nAdherence\n\nPoor adherence to urate-lowering therapy is widely documented and is a major reason treatment fails. A meta-analysis cited in a later cohort study put overall long-term adherence at about 47%, although estimates vary with the measurement method. In a study of 4,166 patients in two US integrated health systems who began urate-lowering drugs between 2000 and 2006, 56% had a medication possession ratio below 0.8 in the first year. Non-adherence was more likely among younger patients, those with fewer comorbidities, people who had no gout-related provider visit before starting treatment, and those who used NSAIDs in the preceding year. In the Norwegian NOR-Gout cohort, younger age and non-European origin were linked to non-adherence, and after five years, patients who were non-adherent had more flares and were less likely to reach the urate target.\n\nFactors that limit access\n\nAccess problems are multifactorial. Suboptimal management is associated with avoidable morbidity and higher costs of care, which places a burden on health systems. Patients who are younger or of non-European origin appear to be at higher risk of poor engagement, which suggests that differences in care reflect wider social and cultural circumstances as well as clinical factors. Patients in one qualitative study asked for quicker specialist referral and better communication between general practitioners and rheumatologists, pointing to fragmentation of primary and secondary care as a practical barrier.\n\nPharmacist-led, nurse-led and telehealth models\n\nNon-physician models of care are among the most studied responses. In the GUARD trial, 99 adults with recurrent gout and raised urate were randomised to pharmacist-managed telephone care or usual physician care. Over 26 weeks, the intervention group's mean urate fell by 1.5 mg/dL, while the control group's rose slightly. A larger site-randomised trial in 1,463 patients at 116 Kaiser Permanente sites in southern California used a pharmacist-led program delivered mainly by automated telephone technology. It improved adherence and the proportion achieving the urate goal at one year. Those gains were reduced in the second year, when the urate-goal difference remained significant but the adherence difference did not. A UK randomised trial found that nurse-led care with education and a treat-to-target strategy was more effective than usual general-practice care, with urate levels optimised more quickly. In a smaller uncontrolled Kaiser programme of 158 enrolled patients, 70% reached the target during the telephone phase. Telehealth also appears to help patients who have work or family commitments, as nurse-led telehealth clinics report that remote appointments make attendance easier, although evidence on eHealth applications specifically remains limited. Trials of pharmacist-led and nurse-led telehealth models are ongoing.\n\nPublic health implications\n\nGout prevalence has risen over recent decades in many countries, while adherence to urate-lowering therapy has stayed suboptimal. This combination means that the number of people needing long-term monitoring is increasing faster than the capacity of primary-care services to deliver it. Because the core drugs are inexpensive and the monitoring tasks are well defined, the gap is largely one of organisation and delivery rather than of available treatment, which makes it a central concern for health-system planning."
    }
  ],
  "links": [
    "metabolism",
    "innate-immunity",
    "inflammation",
    "obesity",
    "hypertension",
    "chronic-kidney-disease",
    "cardiovascular-disease",
    "enzyme",
    "polarization",
    "nucleotide",
    "ph",
    "temperature",
    "kidney",
    "epidemiology",
    "genetics",
    "ultrasonography",
    "ethanol",
    "type-two-diabetes"
  ],
  "sources": [
    {
      "title": "Gout and Pseudogout Differential Diagnoses",
      "url": "https://emedicine.medscape.com/article/329958-differential"
    },
    {
      "title": "Gout - Rheumatology and Orthopedics - Merck Manual Professional Edition",
      "url": "https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/crystal-induced-arthritides/gout"
    },
    {
      "title": "Diagnosis, Treatment, and Prevention of Gout",
      "url": "https://www.aafp.org/pubs/afp/issues/2014/1215/p831.html"
    },
    {
      "title": "Gout",
      "url": "https://dermnetnz.org/topics/gout"
    },
    {
      "title": "Chronic tophaceous gout with unusual large tophi: case report",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742039/"
    },
    {
      "title": "Ulcerated Tophaceous Gout",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528853/"
    },
    {
      "title": "Gout - Rheumatology and Orthopedics - MSD Manual Professional Edition",
      "url": "https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/crystal-induced-arthritides/gout"
    },
    {
      "title": "(PDF) Clinical features of gout",
      "url": "https://www.researchgate.net/publication/221804208_Clinical_features_of_gout"
    },
    {
      "title": "The Clinical Features of Gout",
      "url": "https://link.springer.com/chapter/10.1007/978-1-84800-934-9_34"
    },
    {
      "title": "Pseudogout vs. gout: Understanding the differences",
      "url": "https://www.medicalnewstoday.com/articles/pseudogout-vs-gout"
    },
    {
      "title": "Pseudogout versus Gout",
      "url": "https://www.news-medical.net/health/Pseudogout-versus-Gout.aspx"
    },
    {
      "title": "Pseudo Gout vs Gout: Key Differences Explained",
      "url": "https://int.livhospital.com/pseudo-gout-vs-gout-key-differences-explained/"
    },
    {
      "title": "Gout",
      "url": "https://geekymedics.com/gout/"
    },
    {
      "title": "Regulation of uric acid metabolism and excretion - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S0167527315303429"
    },
    {
      "title": "Hyperuricemia and its related diseases: mechanisms and advances in therapy",
      "url": "https://www.nature.com/articles/s41392-024-01916-y"
    },
    {
      "title": "Frontiersin",
      "url": "https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1662037/xml"
    },
    {
      "title": "Uric Acid Puzzle: Dual Role as Anti-oxidantand Pro-oxidant - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4105384/"
    },
    {
      "title": "The Role of Uric Acid in Human Health: Insights from the Uricase Gene",
      "url": "https://www.mdpi.com/2075-4426/13/9/1409"
    },
    {
      "title": "Full article: Is uric acid a true antioxidant? Identification of uric acid oxidation products and their biological effects",
      "url": "https://www.tandfonline.com/doi/full/10.1080/13510002.2025.2498105"
    },
    {
      "title": "Urate transporter, as well as method and kit for evaluating urate transport-related disease factor and inflammation-related disease factor, and test sample and drug",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8940286"
    },
    {
      "title": "Role of urate transporters in the kidneys and intestine in uric acid homeostasis",
      "url": "https://www.krcp-ksn.org/journal/view.php?number=6474&viewtype=pubreader"
    },
    {
      "title": "The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout—An Update",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268734/"
    },
    {
      "title": "Urate Transporter - an overview",
      "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/urate-transporter"
    },
    {
      "title": "Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277506/"
    },
    {
      "title": "PEG-modified uricase",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6913915"
    },
    {
      "title": "Biochemistry, Xanthine Oxidase - StatPearls - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK545245/?report=printable"
    },
    {
      "title": "Frontiers",
      "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2018.00160/full"
    },
    {
      "title": "Hyperuricemia - an overview",
      "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/hyperuricemia"
    },
    {
      "title": "Full article: Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?",
      "url": "https://www.tandfonline.com/doi/full/10.1080/00325481.2016.1221732"
    },
    {
      "title": "Hyperuricemia - WikEM",
      "url": "https://wikem.org/wiki/Hyperuricemia"
    },
    {
      "title": "Treatment of gout",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9402827"
    },
    {
      "title": "Uric Acid: Reference Range, Interpretation, Collection and Panels",
      "url": "https://emedicine.medscape.com/article/2088516-overview"
    },
    {
      "title": "Hyperuricemia Treatment & Management: Medical Care, Consultations, Diet",
      "url": "https://emedicine.medscape.com/article/241767-treatment"
    },
    {
      "title": "Asymptomatic hyperuricemia: the case for conservative management - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/646260/"
    },
    {
      "title": "Treatment of Asymptomatic Hyperuricemia: When do you have a good reason to provide therapy? - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21228996/"
    },
    {
      "title": "Gout and hyperuricaemia: modifiable cardiovascular risk factors?",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248051/"
    },
    {
      "title": "Hyperuricemia remodels the serum proteome toward a higher inflammatory state",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550725/"
    },
    {
      "title": "Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12975706/"
    },
    {
      "title": "Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25180131/"
    },
    {
      "title": "Why Does Hyperuricemia Not Necessarily Induce Gout? - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7918342/"
    },
    {
      "title": "Asymptomatic hyperuricemia: to treat or not to treat - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12184468/"
    },
    {
      "title": "Uric Acid Stones: Practice Essentials, Pathophysiology, Etiology",
      "url": "https://emedicine.medscape.com/article/983759-overview"
    },
    {
      "title": "Uric Acid Metabolism and Homeostasis in Health and Disease - MetwareBio",
      "url": "https://www.metwarebio.com/uric-acid-metabolism-homeostasis/"
    },
    {
      "title": "Renal urate transport - PubMed - NIH",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16716882/"
    },
    {
      "title": "Uric Acid Urine Level - an overview",
      "url": "https://www.sciencedirect.com/topics/immunology-and-microbiology/uric-acid-urine-level"
    },
    {
      "title": "Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010",
      "url": "https://clinicaltrials.gov/study/NCT00175019"
    },
    {
      "title": "Gout and Pseudogout: Background, Etiology, Pathophysiology",
      "url": "https://emedicine.medscape.com/article/329958-overview"
    },
    {
      "title": "Diagnosis of Gout : Urate Crystals in Synovial Fluid",
      "url": "https://www.webpathology.com/images/orthopedic/lesions-of-joints/gout/40512"
    },
    {
      "title": "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228021/"
    },
    {
      "title": "Monosodium urate crystals",
      "url": "https://link.springer.com/10.1007/3-540-29662-X_1891"
    },
    {
      "title": "Urate Crystal - an overview",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/urate-crystal"
    },
    {
      "title": "Blood-borne phagocytes internalize urate microaggregates and prevent intravascular NETosis by urate crystals",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137018/"
    },
    {
      "title": "(PDF) Mechanisms of crystal formation in gout - A structural approach",
      "url": "https://www.researchgate.net/publication/282040434_Mechanisms_of_crystal_formation_in_gout_-_A_structural_approach"
    },
    {
      "title": "Mechanisms of crystal formation in gout—a structural approach",
      "url": "https://www.nature.com/articles/nrrheum.2015.125"
    },
    {
      "title": "Gout and Pseudogout Workup: Approach Considerations, Synovial Fluid Analysis, Serum Uric Acid",
      "url": "https://emedicine.medscape.com/article/329958-workup"
    },
    {
      "title": "AB1025 Monosodium urate crystal formations from tophi in synovial fluid - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0003496724337719"
    },
    {
      "title": "Gout: The mechanism of urate crystal nucleation and growth. A hypothesis based in facts",
      "url": "https://www.researchgate.net/publication/231611947_Gout_The_mechanism_of_urate_crystal_nucleation_and_growth_A_hypothesis_based_in_facts"
    },
    {
      "title": "Tophaceous Gout simulating infected Ankle Implants",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333689/"
    },
    {
      "title": "Frontiersin",
      "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1847953/xml"
    },
    {
      "title": "Tophus - an overview",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/tophus"
    },
    {
      "title": "From uric acid to tophi: multistage molecular and cellular mechanisms of tophi formation - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42358963/"
    },
    {
      "title": "Frontiers",
      "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1847953/full"
    },
    {
      "title": "Prevention or treatment of uratic or gouty diseases",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10322132"
    },
    {
      "title": "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients",
      "url": "https://www.nature.com/articles/s42003-024-06534-6"
    },
    {
      "title": "Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6311031/"
    },
    {
      "title": "Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4337950/"
    },
    {
      "title": "Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17056568/?dopt=Abstract"
    },
    {
      "title": "Gout. Mechanisms of inflammation in gout",
      "url": "https://link.springer.com/article/10.1186/ar2952"
    },
    {
      "title": "Gout and NLRP3 Inflammasome Biology - Poulsen - 2025 - Arthritis & Rheumatology - Wiley Online Library",
      "url": "https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.43215"
    },
    {
      "title": "Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout",
      "url": "https://www.nature.com/articles/srep38622"
    },
    {
      "title": "Neutrophils, IL-1β, and gout: is there a link?",
      "url": "https://link.springer.com/article/10.1007/s00281-013-0361-0"
    },
    {
      "title": "Frontiers",
      "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1761121/full"
    },
    {
      "title": "JE   Cumpelik et al 2015",
      "url": "https://www.uab.edu/medicine/rheumatology/images/JE_-_Cumpelik_et_al_2015.pdf"
    },
    {
      "title": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4893114"
    },
    {
      "title": "Gout: An old disease in new perspective",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5512152/"
    },
    {
      "title": "Clinical Features| Gout",
      "url": "https://www.healio.com/clinical-guidance/gout/clinical-features-and-natural-course-presentation-and-diagnosis"
    },
    {
      "title": "Understanding Gout Stages: A Complete Guide to Disease Progression",
      "url": "https://goutsavvy.com/gout-stages-progression-complete-guide/"
    },
    {
      "title": "Clinical Aspects of Gout ICD-9-CM Coordination and",
      "url": "https://www.cdc.gov/nchs/ppt/icd9/att7croftsep08.pdf"
    },
    {
      "title": "Serum Urate and Recurrent Gout",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/2814538"
    },
    {
      "title": "Baseline Urate Levels Can Predict Risk of Recurrent Gout Flares - Renal and Urology News",
      "url": "https://www.renalandurologynews.com/news/baseline-urate-levels-can-predict-risk-of-recurrent-gout-flares/"
    },
    {
      "title": "The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10497051/"
    },
    {
      "title": "Tophaceous Gout",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842507/"
    },
    {
      "title": "Gout — Radiology Reference",
      "url": "https://radshare.net/topics/gout"
    },
    {
      "title": "Plain Radiography and Advanced Imaging of Gout",
      "url": "https://musculoskeletalkey.com/plain-radiography-and-advanced-imaging-of-gout/"
    },
    {
      "title": "The pathogenesis of bone erosions in gouty arthritis - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0003496724147814"
    },
    {
      "title": "Gout Flare in Hospitalized Patients: Risk Factors and the Impact of Allopurinol Management - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13183363/"
    },
    {
      "title": "Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263476/"
    },
    {
      "title": "Gout epidemiology and comorbidities - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S0049017220301220"
    },
    {
      "title": "Global burden of gout in the working-age population (15–64 years), 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021",
      "url": "https://www.medrxiv.org/content/10.64898/2026.01.30.26345202v1.full"
    },
    {
      "title": "Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327586/"
    },
    {
      "title": "Gout Across Genders: Prevalence, Diagnosis, and Management - Gout Education",
      "url": "https://gouteducation.org/gout-across-genders-prevalence-diagnosis-and-management/"
    },
    {
      "title": "Obesity and Genetics Together Raise Gout Risk in Women",
      "url": "https://creakyjoints.org/about-arthritis/gout/gout-overview/gout-risk-women-genetics-obesity/"
    },
    {
      "title": "Case report: Gouty renal abscess and gouty sacroiliitis associated with genetic variants of a young woman",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906439/"
    },
    {
      "title": "Gout: A Review of Nonmodifiable and Modifiable Risk Factors - ScienceDirect",
      "url": "https://sciencedirect.com/science/article/abs/pii/S0889857X14000635?via=ihub%3D"
    },
    {
      "title": "Genetic Association Between Sex Hormones, Serum Urate, and Gout: A Comprehensive Mendelian Randomization Study - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42016019/"
    },
    {
      "title": "Association between serum urate, gout and chronic kidney disease: a scoping review of systematic reviews and meta-analyses - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12455028/"
    },
    {
      "title": "Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494879/"
    },
    {
      "title": "Gout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678569/"
    },
    {
      "title": "Gout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications",
      "url": "https://www.mdpi.com/2077-0383/13/24/7616"
    },
    {
      "title": "Management of gout in advanced renal disease",
      "url": "https://www.explorationpub.com/Journals/emd/Article/100791"
    },
    {
      "title": "Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population",
      "url": "https://link.springer.com/article/10.1186/s12882-019-1274-5"
    },
    {
      "title": "Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10397893/"
    },
    {
      "title": "Urate Crystals; Beyond Joints - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8212931/"
    },
    {
      "title": "Frontiersin",
      "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.649505/xml"
    },
    {
      "title": "Systemic Urate Deposition: An Unrecognized Complication of Gout?",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600842/"
    },
    {
      "title": "Systemic Urate Deposition: An Unrecognized Complication of Gout?",
      "url": "https://www.mdpi.com/2077-0383/9/10/3204"
    },
    {
      "title": "Presence of tophi is associated with a rapid decline in the renal function in patients with gout - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7952381/"
    },
    {
      "title": "Gout comorbidities: results from the Korean National Health and Nutrition Examination Survey",
      "url": "https://link.springer.com/article/10.1186/s42358-024-00413-8"
    },
    {
      "title": "Association between Hyperuricemia and Metabolic Syndrome: An Epidemiological Study of a Labor Force Population in Taiwan",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529909/"
    },
    {
      "title": "Association of Obesity based on Different Metabolic Status with Risk of Gout Occurrence in Patients: A National Study - ScienceDirect",
      "url": "https://www.sciencedirect.com/org/science/article/pii/S1871530324000027"
    },
    {
      "title": "Metabolic dysfunction-associated fatty liver disease and the risk of gout: a UK Biobank prospective cohort study",
      "url": "https://link.springer.com/article/10.1186/s40001-025-03298-5"
    },
    {
      "title": "Multi-dimensional evidence establishing the causal association between metabolic syndrome and gout and the molecular mechanisms of comorbidity - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12956786/"
    },
    {
      "title": "Assessing Elementary Lesions in Gout by Ultrasound: Results of an OMERACT Patient-based Agreement and Reliability Exercise",
      "url": "https://www.jrheum.org/content/42/11/2149"
    },
    {
      "title": "Ultrasound Findings of Monosodium Urate Aggregates in Patients with Gout",
      "url": "https://www.mdpi.com/2813-4583/1/2/8"
    },
    {
      "title": "Gout Classification Criteria: Update and Implications - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4981244/"
    },
    {
      "title": "2015 Gout Classification Criteria| Clinical Guidance",
      "url": "https://www.healio.com/clinical-guidance/gout/synopsis-and-assessment-of-the-2015-gout-classification-criteria-treatment-guidelines"
    },
    {
      "title": "2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26359487/"
    },
    {
      "title": "Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout",
      "url": "https://cdn.clinicaltrials.gov/large-docs/73/NCT03636373/Prot_003.pdf"
    },
    {
      "title": "Consensus-based semi-quantitative ultrasound scoring system for gout lesions: Results of an OMERACT Delphi process and web-reliability exercise - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0049017221000056"
    },
    {
      "title": "Imaging of gout: an atlas",
      "url": "https://academic.oup.com/rheumap/article/9/2/rkaf051/8156941"
    },
    {
      "title": "Ultrasonography in gout: utility in diagnosis and monitoring",
      "url": "https://www.clinexprheumatol.org/article.asp?a=13341"
    },
    {
      "title": "Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24671771/"
    },
    {
      "title": "Dual-energy computed tomography has limited diagnostic sensitivity for short-term gout",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835052/"
    },
    {
      "title": "ACR-EULAR Gout Classification Criteria Clinical Calculator and Pathways - Guideline Central",
      "url": "https://www.guidelinecentral.com/calculator/443/"
    },
    {
      "title": "2015 ACR/EULAR Classification Criteria for Gout Calculator",
      "url": "https://www.mdcalc.com/calc/2195/2015-acr-eular-classification-criteria-gout"
    },
    {
      "title": "Ultrasound Features in Gout: An Overview",
      "url": "https://doi.org/10.3390/medsci12030037"
    },
    {
      "title": "The comprehensive role of dual-energy CT in gout as an advanced diagnostic innovation - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39690304"
    },
    {
      "title": "Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758140/"
    },
    {
      "title": "Dual-energy CT: A New Diagnostic Tool for Gout",
      "url": "https://www.medscape.com/viewarticle/754878"
    },
    {
      "title": "Dual-Energy CT Accurately Diagnoses Urate Crystal Deposition in Gout; Limited Sensitivity for Short-Stage Gout - Rheumatology Advisor",
      "url": "https://www.rheumatologyadvisor.com/news/dect-accurately-diagnoses-msu-crystal-deposition-in-gout/"
    },
    {
      "title": "(PDF) 2020 American College of Rheumatology Guideline for the Management of Gout",
      "url": "https://www.researchgate.net/publication/341287675_2020_American_College_of_Rheumatology_Guideline_for_the_Management_of_Gout"
    },
    {
      "title": "Management of Gout: Update from the American College of Rheumatology",
      "url": "https://www.aafp.org/pubs/afp/issues/2021/0800/p209.html"
    },
    {
      "title": "Update on colchicine, 2017 - PMC - NIH",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5850858/"
    },
    {
      "title": "Gout Attack Treatment: How to Stop a Flare",
      "url": "https://teledirectmd.com/health-guides/gout-attack-treatment-guide/"
    },
    {
      "title": "What is the recommended dose of colchicine for a gout flare-up?",
      "url": "https://www.droracle.ai/articles/627208/what-is-the-recommended-dose-of-colchicine-for-a"
    },
    {
      "title": "Updated 2020 American College of Rheumatology Gout Management Guidelines - Rheumatology Advisor",
      "url": "https://www.rheumatologyadvisor.com/features/updated-2020-acr-gout-management-guidelines/"
    },
    {
      "title": "Rheumatology Following New Gout Treatment Guidelines ...",
      "url": "https://www.medcentral.com/rheumatology/following-new-gout-treatment-guidelines"
    },
    {
      "title": "Gout: Treatment of flares - UpToDate",
      "url": "https://www.uptodate.com/contents/gout-treatment-of-flares"
    },
    {
      "title": "Treatment Options for Gout",
      "url": "https://www.uspharmacist.com/article/treatment-options-for-gout"
    },
    {
      "title": "2020 ARC Guidelines",
      "url": "https://www.healio.com/clinical-guidance/gout/2020-american-college-of-rheumatology-guidelines-for-the-management-of-gout-treatment-guidelines"
    },
    {
      "title": "Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study",
      "url": "https://www.researchgate.net/publication/324448783_Effectiveness_and_safety_of_anakinra_in_gout_patients_with_stage_4-5_chronic_kidney_disease_or_kidney_transplantation_A_multicentre_retrospective_study"
    },
    {
      "title": "Interleukin-1 Inhibitors for Acute Gout Flares: A Systematic Review and Meta-analysis",
      "url": "https://www.scientificarchives.com/article/interleukin-1-inhibitors-for-acute-gout-flares-a-systematic-review-and-meta-analysis"
    },
    {
      "title": "Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1297319X18300587"
    },
    {
      "title": "IL-1β-Targeted Therapy May Help Alleviate Gout Flares Among Patients Refractory to Standard Therapies - Rheumatology Advisor",
      "url": "https://www.rheumatologyadvisor.com/news/canakinumab-and-rilonacept-may-help-reduce-gout-flare-frequency/"
    },
    {
      "title": "CD009993 interleukin 1 inhibitors acute gout",
      "url": "https://www.cochrane.org/evidence/CD009993_interleukin-1-inhibitors-acute-gout"
    },
    {
      "title": "2020 American College of Rheumatology Guideline for the Management of Gout - FitzGerald - 2020 - Arthritis Care & Research - Wiley Online Library",
      "url": "https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24180"
    },
    {
      "title": "What is the proper dosing of colchicine (Colcrys) for managing a gout attack?",
      "url": "https://www.droracle.ai/articles/614223/what-is-the-proper-dosing-of-colchicine-colcrys-for"
    },
    {
      "title": "Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367374/"
    },
    {
      "title": "Gout therapy updated - Kate L. McCarty, Angelo L. Gaffo, Cesar Diaz-Torne, 2025",
      "url": "https://journals.sagepub.com/doi/10.1177/1759720X251384584"
    },
    {
      "title": "Urate-Lowering Therapy| Gout",
      "url": "https://www.healio.com/clinical-guidance/gout/pharmacologic-urate-lowering-therapy-assessment-and-treatment"
    },
    {
      "title": "2020 ACR Gout Guidelines for Allopurinol Have Changed!",
      "url": "https://deceraclinical.com/education/the-exchange/2020-acr-gout-guidelines-for-allopurinol-have-changed-"
    },
    {
      "title": "American College of Rheumatology Guideline for the Management of Gout - PcMED Project",
      "url": "https://pcmedproject.com/rheumatology/american-college-of-rheumatology-guideline-for-the-management-of-gout/"
    },
    {
      "title": "2020 American College of Rheumatology Guideline for the ...",
      "url": "https://dashboard.protocolosclinicos.com.br/download/anexo/2271/documento-oficial-acr.pdf"
    },
    {
      "title": "Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out - ACR Meeting Abstracts",
      "url": "https://acrabstracts.org/abstract/identifying-optimal-serum-urate-levels-to-reduce-gout-flares-in-patients-taking-urate-lowering-therapy-a-post-hoc-cohort-analysis-of-cares-with-consideration-of-drop-out/"
    },
    {
      "title": "Achievement of serum uric acid target by rheumatology clinic pharmacists compared with primary care providers in patients with gout - Journal of the American Pharmacists Association",
      "url": "https://www.japha.org/article/S1544-3191(22)00391-0/fulltext"
    },
    {
      "title": "Press Release: Gout Management Guideline",
      "url": "https://rheumatology.org/press-releases/acr-releases-gout-management-guideline-with-emphasis-on-treat-to-target-strategy-for-urate-lowering-therapy"
    },
    {
      "title": "Management of Gout: Update from the American College of Rheumatology",
      "url": "https://www.aafp.org/afp/2021/0800/p209"
    },
    {
      "title": "Diagnosis and management of gout: are the British Society for Rheumatology and National Institute for Health and Care Excellence guidelines both needed?",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809909/"
    },
    {
      "title": "Treating to Target in Gout: The Trouble with Serum Urate - The Rheumatologist",
      "url": "https://www.the-rheumatologist.org/article/treating-to-target-in-gout-the-trouble-with-serum-urate/"
    },
    {
      "title": "Controversies in Urate-Lowering Therapy for Gout: A Comprehensive Review - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13480399/"
    },
    {
      "title": "Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians",
      "url": "https://www.acpjournals.org/doi/10.7326/M16-0570"
    },
    {
      "title": "Allopurinol for Gout: When to Start, Titrate, and When to Stop",
      "url": "https://www.uniqcret.com/post/allopurinol-gout-guide"
    },
    {
      "title": "Guidelines for Treating Gout",
      "url": "https://www.arthritis.org/diseases/more-about/gout-treatment-guidelines"
    },
    {
      "title": "Guidelines for the treatment of gout: a Swiss perspective",
      "url": "https://smw.ch/index.php/smw/article/download/2218/3316?inline=1"
    },
    {
      "title": "Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879341/"
    },
    {
      "title": "Gout flare prevention methods using IL-1BETA blockers",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12269875"
    },
    {
      "title": "Prophylaxis of Acute Gout Flares",
      "url": "https://www.healio.com/clinical-guidance/gout/prophylaxis-of-acute-gout-flares-assessment-and-treatment"
    },
    {
      "title": "New Gout Guidance Promotes Treat-to-Target Urate-Lowering Therapy",
      "url": "https://www.uspharmacist.com/article/new-gout-guidance-promotes-treattotarget-urate-lowering-therapy"
    },
    {
      "title": "National Institute for Health and Care Excellence Guideline version (Final)",
      "url": "https://www.nice.org.uk/guidance/ng219/evidence/h-colchicine-nsaids-corticosteroids-and-il1-inhibitors-for-the-prevention-of-gout-flares-during-the-initiation-or-titration-of-uratelowering-therapy-pdf-11080521333"
    },
    {
      "title": "Update on Gout Management: what’s old and what’s new - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8799507/"
    },
    {
      "title": "Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646835/"
    },
    {
      "title": "Primary care gout patients often discontinue allopurinol",
      "url": "https://www.mdedge.com/rheumatology/article/109873/gout/primary-care-gout-patients-often-discontinue-allopurinol"
    },
    {
      "title": "Rates of adherence and persistence with allopurinol therapy among gout patients in Israel - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23392592/"
    },
    {
      "title": "Allopurinol adherence and its predictors in gout: a national cohort study in US veterans - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S2665991320300291"
    },
    {
      "title": "Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)",
      "url": "https://academic.oup.com/rheumatology/article/57/9/1641/5035082"
    },
    {
      "title": "Optimizing adherence to allopurinol for gout: patients' perspectives - Spragg - 2023 - British Journal of Clinical Pharmacology - Wiley Online Library",
      "url": "https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15657"
    },
    {
      "title": "Uncontrolled Chronic Gout Management Guidelines and Options",
      "url": "https://www.neverendinggout.com/management/gout-management-guidelines"
    },
    {
      "title": "Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa035700"
    },
    {
      "title": "5 Best and Worst Foods for Gout: A Simple Guide to Lower Uric Acid",
      "url": "https://www.kidney.org/news-stories/what-to-eat-and-avoid-if-you-have-gout"
    },
    {
      "title": "7 Foods That Trigger Gout - University of Maryland Medical System Health Hub",
      "url": "https://health.umms.org/rheumatology/7-foods-that-trigger-gout/"
    },
    {
      "title": "Mediterranean Diet for Gout: Foods to Enjoy and Avoid - Summit Rheumatology",
      "url": "https://summitrheumatology.com/patient-lifestyle/mediterranean-diet-for-gout/"
    },
    {
      "title": "Eat This, Not That: Foods You Can Still Enjoy if You Are Living With Gout",
      "url": "https://www.healthcentral.com/slideshow/what-to-eat-with-gout"
    },
    {
      "title": "Consumption of Total and Specific Alcoholic Beverages and Long-Term Risk of Gout Among Men and Women",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822906"
    },
    {
      "title": "s12891 015 0661 8",
      "url": "https://link.springer.com/doi/10.1186/s12891-015-0661-8"
    },
    {
      "title": "Exploring the Relationship Between Alcohol Consumption and Gout: A Narrative Review - Martínez‐Ávila - 2025 - International Journal of Rheumatic Diseases - Wiley Online Library",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/1756-185x.70421?af=R"
    },
    {
      "title": "Fructose-Rich Beverages and Risk of Gout in Women",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/186958"
    },
    {
      "title": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3058904"
    },
    {
      "title": "High consumption of sugary soft drinks increases the risk of gout in men",
      "url": "https://www.nature.com/articles/ncprheum0776"
    },
    {
      "title": "Consumption of sugar sweetened beverages and dietary fructose in relation to risk of gout and hyperuricemia: a systematic review and meta-analysis",
      "url": "https://www.researchgate.net/publication/328033631_Consumption_of_sugar_sweetened_beverages_and_dietary_fructose_in_relation_to_risk_of_gout_and_hyperuricemia_a_systematic_review_and_meta-analysis"
    },
    {
      "title": "Frontiers",
      "url": "https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1669129/full"
    },
    {
      "title": "Sugar-sweetened beverages and the risk of hyperuricemia and gout: a meta-analysis",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12580599/"
    },
    {
      "title": "A concise history of gout and hyperuricemia and their treatment",
      "url": "https://link.springer.com/article/10.1186/ar1906"
    },
    {
      "title": "Gout",
      "url": "https://en.wikipedia.org/wiki/Gout"
    },
    {
      "title": "(PDF) Gout in the writings of eminent ancient Greek and Byzantine physicians",
      "url": "https://www.researchgate.net/publication/51764541_Gout_in_the_writings_of_eminent_ancient_Greek_and_Byzantine_physicians"
    },
    {
      "title": "(PDF) A concise history of gout and hyperuricemia and their treatment",
      "url": "https://www.researchgate.net/publication/6965018_A_concise_history_of_gout_and_hyperuricemia_and_their_treatment"
    },
    {
      "title": "Gout: a history of theories and treatments",
      "url": "https://www.pharmaceutical-journal.com/opinion/comment/gout-a-history-of-theories-and-treatments/10989626.article?firstPass=false"
    },
    {
      "title": "All About Gout, 'The Disease Of Kings'",
      "url": "https://www.ranker.com/list/medieval-history-of-gout/genevieve-carlton"
    },
    {
      "title": "Cause and Treatment of the Uric Acid Diathesis",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613134/"
    },
    {
      "title": "The \"thread method\" to determine uric acid in blood (Garrod, 1859).",
      "url": "https://www.researchgate.net/figure/The-thread-method-to-determine-uric-acid-in-blood-Garrod-1859_fig3_221804204"
    },
    {
      "title": "Irregular Gout, Asymptomatic Hyperuricaemia and the Role of Treatment",
      "url": "https://www.mdpi.com/2813-4583/4/1/7"
    },
    {
      "title": "Understanding the Role of Uric Acid in Gout - The Rheumatologist",
      "url": "https://www.the-rheumatologist.org/article/understanding-the-role-of-uric-acid-in-gout/?singlepage=1"
    },
    {
      "title": "Gout: A modern resurgence of an ancient disease",
      "url": "https://utswmed.org/medblog/gout-inflammatory-arthritis/"
    },
    {
      "title": "Gout : Introduction to Gout",
      "url": "https://www.hopkinsarthritis.org/arthritis-info/gout/"
    },
    {
      "title": "Gout - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31536213/"
    },
    {
      "title": "Gout in the “Anonymus Parisinus”",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12712072/"
    },
    {
      "title": "Evolutionary history and metabolic insights of ancient mammalian uricases - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3956161/"
    },
    {
      "title": "Theodore E. Woodward Award: The Evolution of Obesity: Insights from the Mid- Miocene - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2917125/"
    },
    {
      "title": "A widely distributed gene cluster compensates for uricase loss in hominids: Cell",
      "url": "https://www.cell.com/cell/fulltext/S0092-8674(23)00687-6"
    },
    {
      "title": "Uric acid and evolution",
      "url": "https://www.researchgate.net/publication/45185205_Uric_acid_and_evolution"
    },
    {
      "title": "Uric acid and cardiovascular disease—recent evidence on the association and underlying mechanisms - Ndrepepa - Journal of Laboratory and Precision Medicine",
      "url": "https://jlpm.amegroups.org/article/view/10145/html"
    },
    {
      "title": "Serum uric acid, the endothelium and hypertension: an association revisited",
      "url": "https://www.nature.com/articles/1002239"
    },
    {
      "title": "Uric Acid: A Danger Signal From the RNA World That May Have a Role in the Epidemic of Obesity, Metabolic Syndrome, and Cardiorenal Disease: Evolutionary Considerations - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0270929511001197"
    },
    {
      "title": "My Case Against Uricase: A critical examination of hypotheses L. Amber O'Hearn",
      "url": "https://escholarship.org/content/qt4hn1r889/qt4hn1r889_noSplash_2283bca0cfe3d0045e9dcc9b3dfd8089.pdf?t=qa83ta"
    },
    {
      "title": "Uric acid and evolution",
      "url": "https://academic.oup.com/rheumatology/article/49/11/2010/1785765"
    },
    {
      "title": "Uricase deficiency in rats results in a variety of metabolic disorders, addition to gouty nephropathy",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373213/"
    },
    {
      "title": "Evolution of Uric Acid Metabolism in Humans - Alvarez‐Lario - Major Reference Works - Wiley Online Library",
      "url": "https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0024618"
    },
    {
      "title": "Uric Acid: A Danger Signal From the RNA World That May",
      "url": "https://biotech.gsu.edu/gauchergroup/papers/Gaucher%20Johnson%20Seminar%20Neph%202011.pdf"
    },
    {
      "title": "URAT1 inhibition in hyperuricemia and gout: from transporter biology to clinical precision therapy - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13527437/"
    },
    {
      "title": "How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present",
      "url": "https://www.explorationpub.com/Journals/emd/Article/100777"
    },
    {
      "title": "Novel gout therapies demonstrate early promise in recent studies",
      "url": "https://www.ccjm.org/page/acr-2025/novel-gout-therapies"
    },
    {
      "title": "REDUCE 2 Trial: Pozdeutinurad Significantly Lowers Serum Uric Acid in Gout - Rheumatology Advisor",
      "url": "https://www.rheumatologyadvisor.com/news/reduce-2-trial-pozdeutinurad-gout/"
    },
    {
      "title": "Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors for Uricosuria - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12802067"
    },
    {
      "title": "Combination of sodium-glucose cotransporter type 2 inhibitors and urate-lowering therapy in people with gout from a specialist clinic: a retrospective, single-center observational study",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12832974/"
    },
    {
      "title": "Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40601087/"
    },
    {
      "title": "Study Positions SGLT2 Inhibitors as Gout Treatment - Mass General Advances in Motion",
      "url": "https://advances.massgeneral.org/rheumatology/article.aspx?id=1545"
    },
    {
      "title": "Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial - The Lancet Rheumatology",
      "url": "https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30065-5/abstract"
    },
    {
      "title": "Targeting the NLRP3 inflammasome for inflammatory disease therapy - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S0165614725000732"
    },
    {
      "title": "Z1456467176 alleviates gouty arthritis by allosterically modulating P2X7R to inhibit NLRP3 inflammasome activation",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424684/"
    },
    {
      "title": "Diabetes and gout: another role for SGLT2 inhibitors?",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311190/"
    },
    {
      "title": "How URAT1 inhibitors can shape the future of chronic gout ...",
      "url": "https://www.explorationpub.com/uploads/Article/A100777/100777.pdf"
    },
    {
      "title": "FDA Roundup: Pipeline Drugs for Gout - Rheumatology Advisor",
      "url": "https://www.rheumatologyadvisor.com/features/fda-roundup-emerging-drug-treatments-for-gout/"
    },
    {
      "title": "Dapansutrile - an overview",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/dapansutrile"
    },
    {
      "title": "Treatment approaches and adherence to urate-lowering therapy for patients with gout - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5403120/"
    },
    {
      "title": "Monitoring and Management of Uric Acid Therapy in Gout and Chronic Kidney Disease: A Single-Center Retrospective Study",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843587/"
    },
    {
      "title": "Adherence to gout guidelines: where do we stand? - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33332889/"
    },
    {
      "title": "Adherence with urate-lowering therapies for the treatment of gout",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688196/"
    },
    {
      "title": "Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study",
      "url": "https://academic.oup.com/rheumatology/article/64/4/1799/7760225"
    },
    {
      "title": "Determinants of gout therapy non-adherence in patients attending an Egyptian rheumatology outpatient clinic - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13528100/"
    },
    {
      "title": "A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4991910/"
    },
    {
      "title": "Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30503879/"
    },
    {
      "title": "Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial - The Lancet",
      "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32158-5/fulltext"
    },
    {
      "title": "Enhancing Gout Management through Nurse-led Telehealth Care",
      "url": "https://www.clinicalexcellence.qld.gov.au/improvement-exchange/enhancing-gout-management-through-nurse-led-telehealth-care"
    },
    {
      "title": "Efficacy and Outcomes of a Novel Telephone-based Gout Disease Management Program - ScienceDirect",
      "url": "https://www.sciencedirect.com/org/science/article/pii/S1874312921000088"
    },
    {
      "title": "Support needs of gout patients and suitability of eHealth to address these needs",
      "url": "https://academic.oup.com/rheumap/article/8/4/rkae125/7811162"
    },
    {
      "title": "Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout",
      "url": "https://clinicaltrials.gov/study/NCT06887452"
    },
    {
      "title": "Nurse-Led Telehealth for Gout",
      "url": "https://clinicaltrials.gov/study/NCT06971146"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}